

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 23:58:07 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Cc: Erbeling, Emily (NIH/NIAID) [E]
Bcc: Dani Bolognesi, Ph.D.
Subject: FW:
Attachments: Brown et al submitted.pdf, NIH Presentation final.pptx, preprints202002.0147.v2 (1).pdf, Mosaheb et al 2020.pdf

Cristina:

Please take a good look at this. It is from Dani Bolognesi, one of our top HIV/AIDS investigators from a few years back. He is a serious scientist. Let me know what you think.
Thanks,
Tony

From: Eisinger, Robert (NIH/NIAID) [E] (b) (6) > **On Behalf Of** Fauci, Anthony (NIH/NIAID) [E]
Sent: Monday, April 27, 2020 6:57 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: FW:

Email from Dani Bolognesi.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone (b) (6) 9
Email (b) (6)

From: Dani Bolognesi, Ph.D. (b) (6) >
Sent: Monday, April 27, 2020 6:09 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Barasch, Kimberly (NIH/NIAID) [C] (b) (6) >
Subject: FW:


Kimberly: Please see that this reaches Tony as per our call today.

TX in advance

Dani

Hi Tony:

In advance of getting together with you and your team, I am forwarding a short presentation for you guys to look at. The key elements are follows:



We are prepared to discuss this with you and your team at any time that is convenient for you. As you may know, we are locked down here in the Research Triangle until May 15. If it makes sense, we could arrange a WebEx as an initial step.

Many thanks for the opportunity to share this with you!

All the very best,

Dani

(b) (6)

Best,

Dani

Sent from Dani Bolognesi

From: "Dani Bolognesi, Ph.D." [REDACTED] (b) (6) >
Date: Monday, April 27, 2020 at 2:53 PM
To: "Matthias Gromeier, M.D." [REDACTED] (b) (6) >
Subject: Please review this draft email to Tony--TX

Matthias: Please review and edit the proposed email to Tony.

Dani

Hi Tony: In advance of getting together with you and your team, I am forwarding a short presentation for you guys to look at. The key elements are follows:



We are prepared to discuss this with you and your tea at any time that is convenient for you. As you may know, we are locked down here in the Research Triangle until May 15. If it makes sense, we could arrange a WebEX as an initial step.

All the best,

Dani

Best,

Dani

Sent from Dani Bolognesi

The information in this electronic mail is sensitive, protected information intended only for the addressee(s). Any other person, including anyone who believes he/she might have received it due to an addressing error, is requested to notify the sender immediately by return electronic mail, and to delete it without further reading or retention. The information is not to be forwarded to or shared unless in compliance with Duke Health policies on confidentiality and/or with the approval of the sender.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 22:35:34 +0000
To: Jeremy Farrar;Dzau, Victor J.;George GAO
Cc: Richard [REDACTED];Hannon, Emma;Conrad, Patricia (NIH/NIAID) [E];Teresa Miller de Vega; [REDACTED];Rebeka Yasmin - CEPI;ben.tinker@cnn.com;Amanda.Sealy@cnn.com;Neel.Khairzada@turner.com;Tia.Miller@turner.com [REDACTED];McGinnis, J. Michael;Balatbat, Celynne;Mun, Jenny; [REDACTED];Redfield, Robert R. (CDC/OD)
Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Jeremy:

Many thanks for the update. Please continue to keep me informed.

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED]
FAX: (301) 496-4409
E-mail: [REDACTED]

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeremy Farrar [REDACTED]
Sent: Tuesday, April 28, 2020 10:39 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED]; Dzau, Victor J. <VDzau@nas.edu>; George GAO [REDACTED]
Cc: Richard Hatchett [REDACTED]; [REDACTED]; Hannon, Emma <EHannon@nas.edu>; Conrad, Patricia (NIH/NIAID) [E] [REDACTED]; Teresa Miller de Vega [REDACTED]; [REDACTED]; Rebeka Yasmin - CEPI [REDACTED]; ben.tinker@cnn.com; Amanda.Sealy@cnn.com; Neel.Khairzada@turner.com; Tia.Miller@turner.com; [REDACTED]; McGinnis, J. Michael [REDACTED]; [REDACTED]; Mun, Jenny <JMun@nas.edu> [REDACTED]; Redfield, Robert R. (CDC/OD) [REDACTED]
Subject: Re: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Quick update

Update in confidence

European network from this morning:

16 Paris, 2 Geneva, few Madrid last 10 days - nothing like this usually seen even with seasonal KD or TSS

Barcelona have slightly different experience of 6 'Kawasaki' in last 2 weeks - couple now who have large coronary aneurysms, as have one child South London and one in Bristol.

Most UK PICU have 1-2 of these type of cases

Phenotype seems Diarrhoea and abdominal pain, refractory shock then various degrees of heart involvement and inflammation ++ - several have had their normal appendix whipped out

Most negative respiratory and stool PCR for anything, some positive resp PCR COVID - GOSH early case has seroconverted, but had immunoglobulin

We are establishing database UK and Europe and trying to define what the clinician features are and agree investigations.

Notably, none in US reported (just D/W Boston childrens who have been running shared international COVID experience web calls) and none in Rome, unsure about rest of Italy yet

Does seem BAME preponderance -?? immune related or social phenomenon, in terms of deprivation prevalence and ability to isolate

From: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>

Date: Monday, 27 April 2020 at 12:36

To: Jeremy Farrar <(b) (6)>, Victor Dzau <VDzau@nas.edu>, George Gao <(b) (6)>

Cc: Richard Hatchett <(b) (6)>

"Hannon, Emma" <EHannon@nas.edu>, "Conrad, Patricia (NIH/NIAID) [E]" <(b) (6)>, Teresa de Vega <(b) (6)>

<(b) (6)> Rebeka Yasmin - CEPI

<(b) (6)>, "ben.tinker@cnn.com" <ben.tinker@cnn.com>,

"Amanda.Sealy@cnn.com" <Amanda.Sealy@cnn.com>, "Neel.Khairzada@turner.com"

<Neel.Khairzada@turner.com>, "Tia.Miller@turner.com" <Tia.Miller@turner.com>,

<(b) (6)> "McGinnis, J. Michael" <MMcGinnis@nas.edu>,

<(b) (6)>, "Mun, Jenny" <JMun@nas.edu>,

<(b) (6)>, "Redfield, Robert R. (CDC/OD)"

<(b) (6)>

Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Jeremy:

Thanks for the heads up. Is there any more detailed description of the precise clinical manifestations? They describe a "multisystem inflammatory state". It is vasculitis or anything more specific? Could be an infectious agent that has nothing to do with SARS-CoV-2 infection even though some children are circumstantially infected with SARS-CoV-2 or it could be a post-SARS-CoV-2 inflammatory syndrome, perhaps a Kawasaki syndrome-like disease. Please keep me informed if you hear any further information.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeremy Farrar (b) (6) >
Sent: Monday, April 27, 2020 7:13 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Dzau, Victor J. <VDzau@nas.edu>; George GAO (b) (6) >
Cc: Richard Hatchett (b) (6) >; Hannon, Emma <EHannon@nas.edu>; Conrad, Patricia (NIH/NIAID) [E] (b) (6) >; Teresa Miller de Vega <(b) (6)>; Rebeka Yasmin - CEPI (b) (6) >; ben.tinker@cnn.com; Amanda.Sealy@cnn.com; Neel.Khairzada@turner.com; Tia.Miller@turner.com; (b) (6) >; McGinnis, J. Michael <MMcGinnis@nas.edu>; (b) (6) >; Mun, Jenny <JMun@nas.edu>; (b) (6) >
Subject: Re: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

To be aware of – news over night so a huge amount of uncertainty – important for COVID19 now, and a potential concern for how we view immunity, protection, post-infectious immunopathology.

<https://www.hsi.co.uk/acute-care/exclusive-national-alert-as-coronavirus-related-condition-may-be-emerging-in-children/7027496.article>

<https://t.co/Bj6YHU8zi>

From: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Date: Sunday, 26 April 2020 at 19:52
To: Victor Dzau <VDzau@nas.edu>, George Gao <(b) (6)>
Cc: Jeremy Farrar <(b) (6)>, Richard Hatchett <(b) (6)>
<(b) (6)>, "Hannon, Emma" <EHannon@nas.edu>, "Conrad, Patricia (NIH/NIAID) [E]" <(b) (6)>, Teresa de Vega <(b) (6)>, Rebeka Yasmin - CEPI <(b) (6)>, "ben.tinker@cnn.com" <ben.tinker@cnn.com>, "Amanda.Sealy@cnn.com" <Amanda.Sealy@cnn.com>, "Neel.Khairzada@turner.com" <Neel.Khairzada@turner.com>, "Tia.Miller@turner.com" <Tia.Miller@turner.com>, <(b) (6)> "McGinnis, J. Michael" <MMcGinnis@nas.edu>, <(b) (6)> "Mun, Jenny" <JMun@nas.edu>, <(b) (6)>
Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

It was a real pleasure to join all of you on this important session. Many thanks for inviting me.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: <(b) (6)>
FAX: (301) 496-4409
E-mail: <(b) (6)>

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Dzau, Victor J. <VDzau@nas.edu>
Sent: Saturday, April 25, 2020 3:59 PM

To: George GAO (b) (6) >
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
(b) (6) Hannon,
Emma <EHannon@nas.edu>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)
(b) (6); rebeka.yasmin@cepi.net; ben.tinker@cnn.com;
Amanda.Sealy@cnn.com; Neel.Khairzada@turner.com; Tia.Miller@turner.com; (b) (6)
McGinnis, J. Michael <MMcGinnis@nas.edu>; (b) (6) >; Mun, Jenny
(b) (6) >; haja.bally@cepi.net
Subject: Re: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Dear Jeremy, Tony, Sanjay, George, Susan and Richard,
Thank you so much for your superb contributions. It was a spectacular session- a truly inspiring one. I am grateful to all of you.
Hope to see you soon.
Warmest regards,
Victor

On Apr 25, 2020, at 1:22 PM, George GAO (b) (6) wrote:

I am waiting for being connected and will use slides which were sent to your office
George

发自我的iPhone

在 2020年4月24日, 01:49, Dzau, Victor J. <VDzau@nas.edu>
写道 :

Dear Jeremy, Tony, Sanjay, George, Susan, and Richard,

I'm really looking forward to this panel on COVID-19 at the NAS Annual Meeting on Saturday, April 25th at 2:00-3:30 pm ET. There is tremendous excitement and enthusiasm, and registration is through the roof.

I am sending this note to do a last minute check to see if there is anything you need from me. I also want to check whether you are planning to use slides. Will you be sending your slides to us to project or use the share screen feature to advance your own slides? Regardless, it would be helpful to me if you could send me your slides for my preparation.

I would greatly appreciate it if you would respond to this email.

Best,
Victor

PS, (b) (6), my special assistant, will be sending you additional information about the session logistics shortly.

From: Dzau, Victor J. <VDzau@nas.edu>

Sent: Thursday, April 9, 2020 11:01 AM

To: Mun, Jenny <JMun@nas.edu>; (b) (6)

(b) (6)

Cc: (b) (6) Hannon, Emma

<EHannon@nas.edu>; (b) (6)

; 'ben.tinker@cnn.com' <ben.tinker@cnn.com>;

'Amanda.Sealy@cnn.com' <Amanda.Sealy@cnn.com>;

'Neel.Khairzada@turner.com' <Neel.Khairzada@turner.com>;

'Tia.Miller@turner.com' <Tia.Miller@turner.com>; (b) (6)

Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Dear all,

Thank you for agreeing to participate in a special late breaking session on the COVID-19 pandemic at the NAS annual meeting. Knowing how busy you are, I am sending this email in lieu of a call to prepare for the session.

As you know, this is a 90 minute session which aims to provide our audience with deeper insights into the latest developments in the COVID-19 response. I plan to hold an engaging discussion that covers the whole experience on dealing with this pandemic – from US to international, to preparedness and response, the biology of the virus, the state of diagnostic, treatment and vaccine development, and the importance of communication.

I will begin the session by providing brief (~3 min) opening remarks describing the circumstances of the pandemic. Then, I will introduce the panelists and you will each have 7 minutes to provide remarks. You

may use a limited number of slides for illustration. I hope that each panelist will provide their own perspective and speak to the issues proposed below.

- Jeremy Farrar will discuss the global response to the pandemic, drawing from his experience as a global leader, the chair of the Scientific Advisory Group for the WHO's R&D Blueprint and as a member of the Global Preparedness Monitoring Board.
- Tony Fauci will discuss the US pandemic and provide his perspective as a member of the White House Coronavirus Task Force addressing the 2019–20 coronavirus pandemic.
- George Gao will discuss China's response to the pandemic and lessons learned for the rest of the globe.
- Susan Weiss will discuss the viral characteristics of SARS COV2 , insights into its pathobiology, immunity and development of a pan-CoV antiviral.
- Richard Hatchett will discuss the development of new vaccines and treatments against COVID-19.
- Sanjay Gupta will comment on the health system response to the pandemic and challenges related to communication and public engagement in responding to COVID-19.

Following remarks from each panelist, we will have a moderated discussion amongst ourselves – I will ask you a set of questions (15 mins) and then we will take questions from the web (25 mins). To prepare me to be your moderator, please send me any questions you would like me to ask you. For those of you who would like to have a prep call, please let me know and I will set it up.

Best,
Victor

From: Mun, Jenny

Sent: Wednesday, April 8, 2020 10:56 AM

To: [REDACTED] (b) (6)

Cc: Dzau, Victor J. ; [REDACTED] (b) (6); Mun, Jenny ; Hannon, Emma ;

[REDACTED] (b) (6)
[REDACTED] ben.tinker@cnn.com' ; 'Amanda.Sealy@cnn.com'
'Neel.Khairzada@turner.com' ; 'Tia.Miller@turner.com'

Subject: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Dear Speakers:

I am the logistical contact for the COVID-19 session that will be held as part of the Annual Meeting (online) program on Saturday, April 25 at 2:00 pm EDT. Thank you for agreeing to participate in this session. To help you with your planning, I have provided additional details below.

Please note that the session will be live webcast and the general public will also be able to watch the session. Video from the session will also be uploaded on the NAS YouTube channel (<https://www.youtube.com/user/theNASciences>) after the meeting. We will need to obtain signed speaker release forms for your participation in this session. I have attached the speaker release form for your review and submission. **Please return the signed speaker release form by Monday, April 13.**

Session speakers are asked to connect 30 minutes prior to the session start time (**by Saturday, April 25 at 1:30 pm EDT**) to allow the technical staff to check connections and prepare for the session. Details on how to connect will be sent before the meeting.

We will list you in our promotional materials as noted below. If this is incorrect, please let me know.

Anthony S. Fauci, Director, National Institute of Allergy and Infectious Diseases

Jeremy Farrar, Director, Wellcome Trust

George F. Gao, Director-General, Chinese Center for Disease Control & Prevention

Sanjay Gupta, Chief Medical Correspondent, CNN

Richard J. Hatchett, CEO, Coalition for Epidemic Preparedness Innovations

Susan R. Weiss, Professor of Microbiology, Perelman School of Medicine, University of Pennsylvania

Since many of us have moved to remote work environments, you may already be proficient with Zoom and other online meeting/collaboration applications. I am attaching a 'speaker guidelines' file in case you have any questions on how best to prepare for and stage your remote talk. We have technical staff available to help you become familiar with Zoom and its settings – such as “sharing your screen” (if you have slide presentations that need to be shown during your talk). We can arrange for a training session this week or next week. If you would like to schedule a session, please let me know as soon as possible.

Dr. Dzau's office will be in touch regarding the agenda for this session. If you have any other questions, please let me know.

Regards, Jenny

Jenny Mun
Membership Director
National Academy of Sciences

[REDACTED] (b) (6)

[REDACTED]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 22:19:19 +0000
To: Alexander Patterson
Subject: RE: (b) (6) made a Video Game of Yo: "Fauci's Revenge"

Thanks, Alex! Much appreciated.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Alexander Patterson <alex.patterson@beatthebomb.com>
Sent: Thursday, April 30, 2020 11:26 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Daniel Lahart <dlahart@regis.org>
Subject: (b) (6) made a Video Game of Yo: "Fauci's Revenge"

Dear Dr. Fauci -

My name is Alex Patterson and I'm (b) (6) I made a video game about you called **Fauci's Revenge**. Link to play: <https://beatthebomb.com/beatthevirus>

We are streaming the Finals of a tournament live tonight at 8 PM EST on Twitch, FB, and YouTube.
Twitch Stream Link (free to watch): <https://www.twitch.tv/beatthebomb1000>

Also available on:

Facebook: <https://www.facebook.com/BeatTheBomb/>

YouTube: <https://www.youtube.com/channel/UC0yh7vo1knuKuaaCKUssAzA>

Please watch the Twitch Stream if you can! Otherwise I will follow up tomorrow with a video!

Media coverage of the Fauci's Revenge in the News:

- NBC New York
Spectrum NY1 News
Timeout New York
News 12 New York
Bushwick Daily
Fox 5 Good Day New York

To date we've raised over \$6,150 for New York City's Public Health System (NYC Health + Hospitals). We've created limited edition t-shirts (including a Fauci's Revenge one). We've donated 6,150 Protective Suits and 4,500 Gloves to the NYC Mayor's Office and face shields to Maimonides Medical Center. Men for others!

Looking forward to being back in the halls soon at a Jug Night or Career Day. Enjoy the game!

Best,

Alex Patterson (b) (6)

--

Alex Patterson

CEO BEAT THE BOMB

www.beatthebomb.com

Follow us on instagram: @beatthebomb

247 Water Street, Suite 106, Brooklyn, 11201

work: 718-643-0200 // cell: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 22:18:45 +0000
To: [REDACTED] (b) (6)
Subject: FW: [REDACTED] (b) (6) Grad made a Video Game of Yo: "Fauci's Revenge"
Attachments: Fauci's Revenge Game Logo.png

Yikes!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Alexander Patterson <alex.patterson@beatthebomb.com>
Sent: Thursday, April 30, 2020 11:26 AM
To: Fauci, Anthony (NIH/NIAID) [E] <afauci@niaid.nih.gov>
Cc: Daniel Lahart <dlahart@regis.org>
Subject: [REDACTED] (b) (6) made a Video Game of Yo: "Fauci's Revenge"

Dear Dr. Fauci -

My name is Alex Patterson and I'm [REDACTED] (b) (6) I made a video game about you called **Fauci's Revenge**. Link to play: <https://beatthebomb.com/beatthevirus>

We are streaming the Finals of a tournament live tonight at 8 PM EST on Twitch, FB, and YouTube.
Twitch Stream Link (free to watch): <https://www.twitch.tv/beatthebomb1000>

Also available on:

Facebook: <https://www.facebook.com/BeatTheBomb/>

YouTube: <https://www.youtube.com/channel/UC0yh7vo1knuKuaaCKUssAzA>

Please watch the Twitch Stream if you can! Otherwise I will follow up tomorrow with a video!

Media coverage of the Fauci's Revenge in the News:

- NBC New York
Spectrum NY1 News
Timeout New York
News 12 New York
Bushwick Daily
Fox 5 Good Day New York

To date we've raised over \$6,150 for New York City's Public Health System (NYC Health + Hospitals). We've created limited edition t-shirts (including a Fauci's Revenge one). We've donated 6,150 Protective Suits and 4,500 Gloves to the NYC Mayor's Office and face shields to Maimonides Medical Center. Men for others!

Looking forward to being back in the halls soon at a Jug Night or Career Day. Enjoy the game!

Best,
Alex Patterson (b) (6)

--

Alex Patterson
CEO BEAT THE BOMB
www.beatthebomb.com
Follow us on instagram: @beatthebomb
247 Water Street, Suite 106, Brooklyn, 11201
work: 718-643-0200 // cell: (b) (6)





BEAT THE BOMB

PRESENTS

FAUCI'S REVENGE

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 22:14:57 +0000
To: (b) (6)
Cc: Tromberg, Bruce (NIH/NIBIB) [E]; Sharpless, Norman (NIH/NCI) [E]; Birx, Deborah L. EOP/NSC; Redfield, Robert R. (CDC/OD); Collins, Francis (NIH/OD) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Stanford National Daily Health Survey for COVID - "Open Up America Again"
Attachments: 4.28.20 NDHS Overview Slides-Rusty-Fauci _ 1.pptx

Rod:

Great to hear from you. Thanks very much for sending this. Very impressive! I will forward this to Bruce Tromberg and Ned Sharpless who have been working on COVID-related apts. In addition, I have cc'd Deb Birx (Coordinator of the White House COVID-19 Task Force) as well as CDC Director Bob Redfield and Francis Collins. I hope that all is well with you. Stay well and safe.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Pettigrew, Roderic I
Sent: Thursday, April 30, 2020 4:20 AM
To: Anthony S. Fauci (NIH/NIAID) (b) (6)
Subject: Stanford National Daily Health Survey for COVID - "Open Up America Again"

Hi Tony,

Greetings from Houston, where the number of cases peaked ~2 weeks ago, dropped 35-40% and seemed to have plateaued since. Great to see you on TV and see the nation (including Brad

Pitt😊) get to know the rigorously informed, keenly rationale and consistently clear Tony your colleagues have long known.

(b) (4), (b) (5)

Thank you, Tony. Very proud to know you. Kind regards to (b) (6).

Rod

Roderic I Pettigrew, PhD, MD

CEO EnHealth | Health Science Center and College of Engineering

Robert A Welch Professor and Executive Dean EnMed | Colleges of Medicine, Engineering and Houston Methodist Hospital

Texas A&M University ALKEK Building|Suite 1103

2121 W Holcombe Blvd | Houston, TX 77030

www.enmed.tamu.edu

Ph: (b) (6) | (b) (6)

MAKING WHAT IF POSSIBLE | whatif.tamu.edu

From: Hofmann, Lawrence, M.D. <[REDACTED]> (b) (6)

Sent: Tuesday, April 28, 2020 11:19 AM

To: Pettigrew, Roderic I [REDACTED] (b) (6)

Cc: Pelc, Norbert J [REDACTED] (b) (6)

Subject: [EXTERNAL]National Daily Health Survey for COVID - "Open Up America Again"



Best,

R

Lawrence "Rusty" Hofmann, MD

Professor and Chief, Interventional Radiology

Medical Director, Digital Health Integration

Medical Director, Cardiac and Interventional Services

@rustyhofmannMD

(m) [REDACTED] (b) (6)

Assistant: [REDACTED] (b) (6)

[REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 22:05:19 +0000
To: Barillas, Carolina (NIH/NIAID) [E]
Cc: Auchincloss, Hugh (NIH/NIAID) [E]
Subject: RE: [REDACTED] (b) (5)

Carolina:

Thanks for sending this [REDACTED] (b) (5)

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)


The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Barillas, Carolina (NIH/NIAID) [E] [REDACTED] (b) (6)
Sent: Thursday, April 30, 2020 11:25 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Cc: Auchincloss, Hugh (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: [REDACTED] (b) (5)

Dear Tony,

[REDACTED] (b) (5)

All the best,
Carolina



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 21:47:05 +0000
To: [REDACTED] (b) (6)
Subject: FW: Autopsy data supporting Remdesivir trial
Attachments: [REDACTED] (b) (4)
[REDACTED]

Take a look at the Figures in the manuscript. [REDACTED] (b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Timothy Schacker [REDACTED] (b) (6)
Sent: Thursday, April 30, 2020 1:10 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Subject: Autopsy data supporting Remdesivir trial

Tony,

[REDACTED] (b) (4)

Stay well (please) and thank you for all you are doing!

Tim
Timothy Schacker, M.D.
Vice Dean for Research, Medical School
Director, Program in HIV Medicine
University of Minnesota


Mail:
MMC 250
420 Delaware Street SE
Minneapolis, MN 55455


FedEx/UPS:
Mayo C688
420 Delaware Street SE
Minneapolis, MN 55455

Phone: (b) (6)

Fax: 612-626-5599

email: (b) (6)





From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 14:17:43 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]
Subject: FW: May the Official Nobel documentary program at Swedish Television get an interview with you Dr Fauci about Covid-19 before May 7th please?

Please get clearance and set it up if possible.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Johan Bergendorff <johan.bergendorff@svt.se>
Sent: Thursday, April 30, 2020 9:56 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: NIAID NEWS (NIH/NIAID) <NIAIDNEWS@niaid.nih.gov>; Barasch, Kimberly (NIH/NIAID) [C] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] (b) (6)
Subject: May the Official Nobel documentary program at Swedish Television get an interview with you Dr Fauci about Covid-19 before May 7th please?

Dear Dr. Fauci,

I had the honor to interview you in april 2016 about the zika epidemic at your office for a program for national Swedish radio as their global health correspondent. I hope I may have the honor again now Sir?

I am now working as science correspondent for the national Swedish Television (non commercial public service, half the population as daily viewers) in our official Nobel prize laureate documentary program "Vetenskapens Värld" (the World of Science) and wonder if you have any chance to give us a 10 minute interview by web video before May 7th please?

I would like to ask you two questions: What is most crucial now to succeed with an covid-19 pandemic exit in the US? How do you find the Swedish strategy against Covid-19 so far (Dr. Mike Ryan praised it yeasterday at the WHO press conference as a model for an exit strategy, what is your view)?

In this one hour program aired on May 11th we will have other prominent scientists as well talking about exit strategies, among others Nobel prize winner prof. Paul Krugman, prof. Bengt Holmström MIT, prof. Angus Deaton Princeton, as well as Prof Gabriel Leung Dean University Hongkong etc.

Here you can see the reports I did from my earlier interview with you about the zika epidemic in 2016 (in Swedish). News report: <https://sverigesradio.se/artikel/6420891> 20 min documentary: <https://sverigesradio.se/avsnitt/712016>

One option is that I send you a link for a web video Conference call. Another option is that I call you on the phone and your media department may have the oportunity to record a video of your anseers with HD quality that is better to air.

Please let me know if you are available and when.

Best regards,

Johan Bergendorff
Science correspondent, Swedish Television

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 13:31:50 +0000
To: Julie.Steenhuysen@thomsonreuters.com
Cc: Greg Folkers (b) (6)
Subject: FW: Fauci says leak concerns fueled his White House revelation of Gilead drug results

Julie:

You did a good job in reporting our conversation last night. Thanks.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Sent: Thursday, April 30, 2020 8:59 AM
To: NIAID COGCORE <COGCORE@mail.nih.gov>; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: Fauci says leak concerns fueled his White House revelation of Gilead drug results

[Health News](#)

April 30, 2020 / 1:07 AM / Updated 4 hours ago

Fauci says leak concerns fueled his White House revelation of Gilead drug results

[Julie Steenhuysen](#)

5 Min Read

CHICAGO (Reuters) - Concerns over leaks compelled the top U.S. infectious disease official to reveal data on Gilead Sciences Inc's experimental drug remdesivir, the first in a scientifically rigorous clinical trial to show benefit in treating COVID-19.



National Institute of Allergy and Infectious Diseases Director Dr. Anthony Fauci attends a coronavirus response meeting between U.S. President Donald Trump and Louisiana Governor John Bel Edwards in the Oval Office at the White House in Washington, U.S., April 29, 2020. REUTERS/Carlos Barria
The dramatic announcement by Dr Anthony Fauci in the Oval Office on Wednesday prompted concerns among scientists that the Trump administration was raising hopes about a coronavirus treatment before sharing the full data with researchers.

As a cautionary example of inflating the potential value of a therapy, some pointed to President Donald Trump's repeated endorsements of malaria drug hydroxychloroquine as a treatment, with no evidence that it works.

Newer data suggests the malaria treatments may carry significant risks for some sufferers of the respiratory disease caused by the virus.

Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), which is running the trial, said he took the first opportunity to get the word out that patients taking a dummy treatment or placebo should be switched to remdesivir in hopes of benefiting from it.

He expressed concern that leaks of partial information would lead to confusion. Since the White House was not planning a daily virus briefing, Fauci said he was invited to release the news at a news conference with Louisiana Gov. John Bel Edwards(D). "It was purely driven by ethical concerns," Fauci told Reuters in a telephone interview.

"I would love to wait to present it at a scientific meeting, but it's just not in the cards when you have a situation where the ethical concern about getting the drug to people on placebo dominates the conversation."

An independent data safety and monitoring board, which had looked at the preliminary results of the NIAID trial, determined it had met its primary goal of reducing hospital stays.

On Tuesday evening, that information was conveyed in a conference call to scientists studying the drug globally.

"There are literally dozens and dozens of investigators around the world," Fauci said. "People were starting to leak it." But he did not give details of where the unreported data was being shared.

Several scientists interviewed by Reuters felt the White House setting seemed inappropriate for the release of highly anticipated government-funded trial data on the Gilead therapy.

They had expected it to be presented simultaneously in a detailed news release, a briefing at a medical meeting or in a scientific journal, allowing researchers to review the data.

Information from various trials of remdesivir has been leaked to media in recent weeks. In a statement on Wednesday, Gilead said the NIAID's much anticipated trial had met its primary goal, but gave no details.

Data in a separate NIAID statement after Fauci spoke detailed preliminary results showing that patients who got the drug had a 31 percent faster time to recovery than those who got a placebo, cutting hospital stays by four days.

The trial also came close to showing the drug helped people survive the disease, but the data fell just short of statistical significance.

"I want to see the full data. I want to understand the statistics. I want to understand the benefit and risk. I want to understand the structure of the study, and all of it," said Dr. Steven Nissen, the chief academic officer at the Cleveland Clinic.

"Am I encouraged from what I've heard? Yes, I'm encouraged. But I want to get a full understanding of what happened here, and not get it via a photo opportunity from the Oval Office."

Data Gilead released on its own trial of remdesivir drew less attention, as it did not compare outcomes between those receiving therapy and those who did not.

Results from a third study in China suggesting remdesivir failed to help COVID-19 patients were released in the British medical journal the Lancet after review by a peer group of scientists.

"That's the only thing I'll hang my hat on, and that was negative," said Dr. Eric Topol, director and founder of the Scripps Research Translational Institute in La Jolla, California.

He was unimpressed by remdesivir's modest benefit.

"It was expected to be a whopping effect," Topol added. "It clearly does not have that."

At the Oval Office news conference, Fauci compared the study findings to AZT, the first drug to show any benefit against HIV, decades ago.

"We know that was an imperfect drug. It was the first step," Fauci said in the interview.

"Similar to AZT, it's (remdesivir) the first baby step towards what hopefully will be a number of better drugs that will come in and be able to treat people with COVID-19."

(This story has been refiled to correct spelling of "clinical" in paragraph one)

Reporting by Julie Steenhuysen; Editing by Michele Gershberg and Clarence Fernandez

Our Standards:[The Thomson Reuters Trust Principles.](#)

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 10:20:32 +0000
To: STEWART SIMONSON (b) (6)
Cc: Masur, Henry (NIH/CC/CCMD) [E]; STEWART SIMONSON
Subject: RE: COVID-19 and Haiti

Bill:

(b) (6) Work with him. As per our prior conversation and as you know better than anyone, Haiti is struggling and I know that Stewart will do whatever he can to assist you.

Warm regards,

Tony

From: STEWART SIMONSON (b) (6)
Sent: Thursday, April 30, 2020 5:44 AM
To: (b) (6)
Cc: Fauci, Anthony (NIH/NIAID) [E]; (b) (6) Masur, Henry (NIH/CC/CCMD) [E]; (b) (6); STEWART SIMONSON (b) (6)
Subject: COVID-19 and Haiti

Dear Dr. Pape:

I lead the World Health Organization (WHO) delegation to the United Nations and know of you through Tony Fauci and Henry Masur, (b) (6). For nearly 5 years immediately preceding my appointment at WHO, I was a technical advisor at Hôpital Sacré-Cœur in Milot and remain in close contact with institution. Because of this, PAHO leadership asked me to join their COVID-19 planning discussions related to Haiti. I understand from Henry that you have been appointed by MSPP to coordinate COVID-19 preparedness and response activities. If you have some time available on Friday, it would be good to talk via Zoom or Webex. I can arrange this and would plan to have the PAHO deputy director as well as other PAHO officials on the line. Would you be available Friday afternoon for such a discussion? If not Friday, anytime over the weekend would also likely work on our end.

Thanks so much for considering this.

With best regards,

Stewart Simonson

STEWART SIMONSON
Washington, DC/New York
(b) (6) or
(b) (6)
(b) (6)S)
IS)
(Switzerland)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 01:24:46 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Has anyone tried palivizumab (Synagis)

Please respond.

From: Rich May [REDACTED] (b) (6)
Sent: Wednesday, April 29, 2020 10:21 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: Has anyone tried palivizumab (Synagis)

Good morning Dr. Fauci,

Has anyone tried palivizumab (Synagis) on any new COVID-19 patients?

Thank you for your time,
Richard May, MD, PhD, D.H.Sc [REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 22:42:24 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: NAD repletion for Covid-19

Please take a look and respond if appropriate

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Mel Cohen (b) (6)
Sent: Wednesday, April 29, 2020 1:52 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: NAD repletion for Covid-19
Importance: High

Dear Dr. Fauci,

Recent research has shown that SARS-CoV-2 plays havoc with NAD function within cells.

Coronavirus Infection and PARP Expression Dysregulate the NAD Metabolome: A Potentially Actionable Component of Innate Immunity:

<https://www.biorxiv.org/content/10.1101/2020.04.17.047480v3>

The Molecular Story of COVID-19; NAD+ Depletion Addresses All Questions in this Infection:

<https://www.preprints.org/manuscript/202003.0346/v1>

Other research has shown that NAD+ levels decline from aging and obesity, both significant factors in Covid-19 severity. But it has also been demonstrated that NAD levels can be replenished through oral administration of nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). NR in particular has had several human studies demonstrating its safety and efficacy, and roughly 50 human studies listed on clinicaltrials.gov for all manner of disorders.

There is at least one anecdotal report of dramatic improvement in a Covid-19 patient after

administration of NMN.

NMN shows great promise in case studies of humans with COVID-19:

https://alivebynature.com/nmn-shows-promise-for-treatment-of-covid-19-in-case-studies/?utm_campaign=NMN%20for%20covid%20%28TqFTyz%29&utm_medium=email&utm_source=Main%20List&_ke=eyJrbF9lbWFpbCI6ICJtZWxhZGlzdHJpYnV0ZWwuY2EiLCAia2xfY29tcGFueV9pZCI6ICJsbWROWFoifQ%3D%3D

That article begins with the disclaimer, "*There are no human trials that prove effectiveness of any NAD+ boosting supplements for preventing or curing COVID-19.*"

That is a problem. When I see the resources that have been wasted pursuing hydroxychloroquine, I am saddened to learn that there are no clinical trials of nicotinamide riboside as part of a treatment regimen for Covid-19. Can you do anything about getting such a study done?

Regards,
Mel Cohen

Disclaimer: [REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 22:01:22 +0000
To: Folkers, Greg (NIH/NIAID) [E]; NIAID OD AM
Subject: RE: ASF----- slides for Business Roundtable, Friday 5-1-2020, 12-1 / FOR REVIEW IN OD

Now FINAL in the OD folder. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Sent: Wednesday, April 29, 2020 5:03 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: ASF----- slides for Business Roundtable, Friday 5-1-2020, 12-1 / FOR REVIEW IN OD

- **This is a zoom call.**
- **I think you will be able to use slides.**
- **I have put in OD a draft "curtain-raiser" set that you could show to kick things off – or use them as TPs if you prefer.**
- **I will update any epi or other numbers tomorrow night**
- **The "ask" is below**

From: Silverberg, Kristen <KSilverberg@brt.org>
Sent: Tuesday, April 14, 2020 4:11 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: invitation from BRT

Dr. Fauci,

First, thank you for everything you are doing. I have always been grateful for your public service, but feel particularly indebted to you these days.

To add to the debt...Josh and I wanted to see if you would be willing to join a call with Business Roundtable CEOs. We have been doing COVID-19 calls with them every Friday at 1:30pm. Typically, about 100-125 CEOs of large, U.S.-based firms will join. They are all managing and planning for difficult issues around employee and customer safety. They would love to hear from you directly and to ask a few questions. It might also be a good place to deliver any messages you want them to hear.

We completely understand if it isn't doable, of course. If you are able, we would love to host you sometime between 1:30pm-2:30pm this Friday (or any Friday on which your schedule would allow it).

Best,

Kristen

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 15:09:44 +0000
To: Anthony Fauci
Subject: FW: Potential slides for Remdesivir presentation
Attachments: Remdesivir bullet slides - FAUCI - FINAL.pptx

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wednesday, April 29, 2020 11:02 AM
To: Short, Marc T. EOP/OVP (b) (6); 'Miller, Katie R. EOP/OVP'
(b) (6) >
Subject: Potential slides for Remdesivir presentation

Marc/Katie:

Here are 3 slides that I might use in the press briefing. If necessary, I could make the presentation without them, but it might be clearer to have them just in case.

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 14:18:44 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Subject: RE: two things

Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, April 29, 2020 9:16 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6)
Subject: ASF: two things

Talked to FDA. They have written (and cleared with Gilead) a new sentence in place of what we had in there about an EUA. Our release has been updated (attached) with the sentence highlighted below.

ALSO: Bill Hall called me to ask if you had alerted the Secretary to this (so the press release clearance process isn't the way he first learns of it). I told him I wasn't sure. If you haven't done so, perhaps you wish to now?

As part of the U.S. Food and Drug Administration's commitment to expediting the development and availability of potential COVID-19 treatments, the agency has been engaged in sustained and ongoing discussions with Gilead Sciences regarding making remdesivir available to patients as quickly as possible, as appropriate.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 10:45:24 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]; Routh, Jennifer (NIH/NIAID) [E]; Stover, Kathy (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]; Erbeling, Emily (NIH/NIAID) [E]
Subject: RE: please read, Gilead statement

Looks fine. Thanks.

From: Billet, Courtney (NIH/NIAID) [E] <billetc@niaid.nih.gov>
Sent: Wednesday, April 29, 2020 6:43 AM
To: Fauci, Anthony (NIH/NIAID) [E] <afauci@niaid.nih.gov>
Cc: Folkers, Greg (NIH/NIAID) [E] <gfolkers@niaid.nih.gov>; Conrad, Patricia (NIH/NIAID) [E] <conradpa@niaid.nih.gov>; Marston, Hilary (NIH/NIAID) [E] <hilary.marston@nih.gov>; Routh, Jennifer (NIH/NIAID) [E] <jennifer.routh@nih.gov>; Stover, Kathy (NIH/NIAID) [E] <kathy.stover@nih.gov>; Lane, Cliff (NIH/NIAID) [E] <clane@niaid.nih.gov>; Erbeling, Emily (NIH/NIAID) [E] <emily.erbeling@nih.gov>
Subject: ASF: please read, Gilead statement

FYI – this will go out before markets open this morning:

GILEAD SCIENCES STATEMENT ON POSITIVE DATA EMERGING FROM NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES' STUDY OF REMDESIVIR

Foster City, Calif., April 29, 2020 – Gilead Sciences, Inc. (Nasdaq: GILD) is aware of the positive data emerging from the National Institute of Allergy and Infectious Diseases' (NIAID) study of remdesivir. We understand that the trial has met its primary endpoint and that NIAID will provide detailed information at an upcoming briefing.

In addition to the NIAID trial, Gilead expects to share additional remdesivir data from the company's open-label Phase 3 SIMPLE trial in patients with severe COVID-19 disease shortly. This study will provide information on whether a shorter, 5-day duration of therapy may have similar efficacy and safety as the 10-day treatment course evaluated in the NIAID trial and other ongoing trials. Gilead expects data at the end of May from the second SIMPLE study evaluating the 5- and 10-day dosing durations of remdesivir in patients with moderate COVID-19 disease.

Gilead will continue to discuss with regulatory authorities the growing data set regarding remdesivir as a potential treatment for COVID-19.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 03:09:03 +0000
To: Berkowitz, Avrahm J. EOP/WHO
Subject: RE: Jared Kushner Defends Dr. Fauci After Fox News Host Criticises Top Coronavirus Task Force Expert

Thanks, Avi.

-----Original Message-----

From: Berkowitz, Avrahm J. EOP/WHO [REDACTED] (b) (6)
Sent: Tuesday, April 28, 2020 10:00 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>
Subject: Jared Kushner Defends Dr. Fauci After Fox News Host Criticises Top Coronavirus Task Force Expert

Just wanted to share an article- all the best!
Avi

<https://www.newsweek.com/jared-kushner-defends-dr-fauci-fox-news-host-little-tough-1500339>

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 03:08:36 +0000
To: Billet, Courtney (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Routh, Jennifer (NIH/NIAID) [E];Erbelding, Emily (NIH/NIAID) [E];Lane, Cliff (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: DRAFT NIAID statement on remdesivir, ACTT 2
Attachments: SHORTENED NIAID statement NEW NEW - with Fauci edits.docx

See my minor edits. [REDACTED] (b) (5)

From: Billet, Courtney (NIH/NIAID) [E] [REDACTED] (b) (6)>
Sent: Tuesday, April 28, 2020 10:40 PM
To: Folkers, Greg (NIH/NIAID) [E] [REDACTED] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [REDACTED] (b) (6)>; Erbelding, Emily (NIH/NIAID) [E] [REDACTED] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] [REDACTED] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] [REDACTED] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: RE: DRAFT NIAID statement on remdesivir, ACTT 2

OK – here’s a re-do. [REDACTED] (b) (5)
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

From: Billet, Courtney (NIH/NIAID) [E]
Sent: Tuesday, April 28, 2020 10:02 PM
To: Folkers, Greg (NIH/NIAID) [E] [REDACTED] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [REDACTED] (b) (6)>; Erbelding, Emily (NIH/NIAID) [E] [REDACTED] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] [REDACTED] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] [REDACTED] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6)>
Subject: RE: DRAFT NIAID statement on remdesivir, ACTT 2

(not sure what happened with spacing). Cliff – I got your suggestion too. I’ll blend yours, mine, and Gregs and send a clean new one shortly.

From: Billet, Courtney (NIH/NIAID) [E]
Sent: Tuesday, April 28, 2020 10:01 PM
To: Folkers, Greg (NIH/NIAID) [E] [REDACTED] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [REDACTED] (b) (6)>; Erbelding, Emily (NIH/NIAID) [E] [REDACTED] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] [REDACTED] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] [REDACTED] (b) (6)>

Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)

Subject: RE: DRAFT NIAID statement on remdesivir, ACTT 2

I took a crack at a revision as well. We can blend these.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)

Sent: Tuesday, April 28, 2020 9:57 PM

To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Routh, Jennifer (NIH/NIAID) [E]

(b) (6)>; Billet, Courtney (NIH/NIAID) [E] <(b) (6)>; Erbelding, Emily

(NIH/NIAID) [E] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] <(b) (6)>; Marston,

Hilary (NIH/NIAID) [E] (b) (6)>

Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>

Subject: RE: DRAFT NIAID statement on remdesivir, ACTT 2

Here is my suggested edit to the short version.

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>

Sent: Tuesday, April 28, 2020 9:21 PM

To: Routh, Jennifer (NIH/NIAID) [E] (b) (6)>; Billet, Courtney (NIH/NIAID) [E]

(b) (6)>; Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Erbelding, Emily

(NIH/NIAID) [E] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] <(b) (6)>; Marston,

Hilary (NIH/NIAID) [E] <(b) (6)>

Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>

Subject: FW: DRAFT NIAID statement on remdesivir, ACTT 2

Importance: High

Thanks for all your work.

(b) (5)

(b) (5)

(b) (5). Please change

this.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)

Sent: Tuesday, April 28, 2020 7:29 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>

Cc: Routh, Jennifer (NIH/NIAID) [E] (b) (6)>; Stover, Kathy (NIH/NIAID) [E]

(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>; Folkers, Greg

(NIH/NIAID) [E] (b) (6)>; Erbelding, Emily (NIH/NIAID) [E] (b) (6)>;

Lane, Cliff (NIH/NIAID) [E] <(b) (6)>; Marston, Hilary (NIH/NIAID) [E]

(b) (6)

Subject: ASF: DRAFT NIAID statement on remdesivir, ACTT 2

Importance: High

There are two versions for your consideration here, as discussed.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 01:53:28 +0000
To: Lane, Cliff (NIH/NIAID) [E]
Subject: RE: Bullets
Attachments: Rendesivir bullet slides - FAUCI.pptx

I added another bullet.

From: Lane, Cliff (NIH/NIAID) [E] (b) (6)
Sent: Tuesday, April 28, 2020 9:51 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: Bullets

Graph inserted.

From: Anthony Fauci (b) (6) >
Date: Tuesday, April 28, 2020 at 9:47 PM
To: "Lane, Cliff (NIH/NIAID) [E]" (b) (6) >
Subject: RE: Bullets

I made some minor changes

From: Lane, Cliff (NIH/NIAID) [E] (b) (6)
Sent: Tuesday, April 28, 2020 9:27 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Bullets

For comment

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 01:50:16 +0000
To: Lane, Cliff (NIH/NIAID) [E]
Subject: RE: DRAFT NIAID statement on remdesivir, ACTT 2
Attachments: ACTT 2 NIAID statement CB KS EE HM HCL1 - with minor edits.docx

(b) (5) I made some minor edits.

From: Lane, Cliff (NIH/NIAID) [E] (b) (6)>
Sent: Tuesday, April 28, 2020 9:44 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: DRAFT NIAID statement on remdesivir, ACTT 2

Attached for consideration.

From: Anthony Fauci (b) (6)>
Date: Tuesday, April 28, 2020 at 9:21 PM
To: "Routh, Jennifer (NIH/NIAID) [E]" (b) (6)>, "Billet, Courtney (NIH/NIAID) [E]" (b) (6)>, "Folkers, Greg (NIH/NIAID) [E]" (b) (6), "Erbelding, Emily (NIH/NIAID) [E]" (b) (6), "Lane, Cliff (NIH/NIAID) [E]" (b) (6)>, Hilary Marston (b) (6)>
Cc: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6)>
Subject: FW: DRAFT NIAID statement on remdesivir, ACTT 2

Thanks for all your work. (b) (5)

(b) (5)
(b) (5). Please change this.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)>
Sent: Tuesday, April 28, 2020 7:29 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Routh, Jennifer (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Erbelding, Emily (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6)
Subject: ASF: DRAFT NIAID statement on remdesivir, ACTT 2
Importance: High

There are two versions for your consideration here, as discussed.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 01:21:27 +0000
To: Routh, Jennifer (NIH/NIAID) [E];Billet, Courtney (NIH/NIAID) [E];Greg Folkers (GFOLKERS@niaid.nih.gov);Erbelding, Emily (NIH/NIAID) [E];Lane, Cliff (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: DRAFT NIAID statement on remdesivir, ACTT 2
Attachments: ACTT 2 NIAID statement CB KS EE HM.docx, SHORTENED NIAID statement.docx

Thanks for all your work. However, [REDACTED] (b) (5)
[REDACTED] (b) (5)
[REDACTED] (b) (5). Please change this.

From: Billet, Courtney (NIH/NIAID) [E] [REDACTED] (b) (6)
Sent: Tuesday, April 28, 2020 7:29 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Cc: Routh, Jennifer (NIH/NIAID) [E] [REDACTED] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] [REDACTED] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6); Folkers, Greg (NIH/NIAID) [E] [REDACTED] (b) (6)>; Erbelding, Emily (NIH/NIAID) [E] [REDACTED] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] [REDACTED] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] [REDACTED] (b) (6)>
Subject: ASF: DRAFT NIAID statement on remdesivir, ACTT 2
Importance: High

There are two versions for your consideration here, as discussed.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 00:56:02 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Coronavirus info about a program that can help.
Attachments: BCA_id_V1 (wecompress.com).pdf

Please take a look and respond if appropriate

-----Original Message-----

From: Alex Holbus [REDACTED] (b) (6)
Sent: Tuesday, April 28, 2020 6:59 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>
Subject: Coronavirus info about a program that can help.

Dear Dr Fauci

It's a pleasure to send you this email my name is Alex Holbus I am from the UK I currently live in Serbia or ex Yugoslavia.
I am a Economist and Humanitarian. I can talk about my Biography but at this time the subject I want to share with you I much more important.

In January 2016 I sent a letter to Mr Trump [REDACTED] (b) (6) telling him that I was happy that he will bring change to America and the world and that if he needed my expertise that I would help your country and the world. As I have not got any responses from him nor his people I can see that he might not be interested. But as I have been following you over the media and be reading about your carrier as a Doctor I believe you know what your doing and would like to take this opportunity to help you and your country at this time when it's the worst then ever before in the modern world. I have a program that can help with the coronavirus in the way of identifying people and following there movement that can help you collect data faster and more sufficient. The program is based on an app so every one can use it. Countries in Europe are starting to use it by the end of May the Europe Union has made it mandatory that all member states need to use it and the future members like Serbia. So you will see attached a presentation about the program and if you or your country is interested please let me know and I will put you in contact with the company making this program. I did not send this email to you so we make money on people it's to help I just wanted to help. I will be contacting my contacts in the USA from Thursday morning but first I wanted to talk with you and give you the opportunity to see if Mr Trump would interested in this program for your country. If nothing comes back from you anyway my friend and contact in the USA will talk with the white house but I wanted to do it the proper way by talking to you as you are the main medical person in the USA for the coronavirus.

Anyway wish you and your country all the best and that the world will become a better place after this epidemic is over.

It's one life one world one human we are all one on this planet no one is bigger or better the all of us as humanity as one.

Kind regards

Alex Holbus

Director at Real Five Company.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Apr 2020 17:41:52 +0000
To: [REDACTED] (b) (6)
Subject: RE: worrisome

Yes. Please call to their attention. [REDACTED] (b) (6) It is merely a nasal swab

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: [REDACTED] (b) (6)
Sent: Tuesday, April 28, 2020 10:32 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: worrisome

From today's Medscape.

https://www.medscape.com/viewarticle/929407?nlid=135287_5653&src=wnl_newsairt_daily_200427_MSCPEDIT&uac=71367AK&impID=2361940&faf=1

Older adults with COVID-19, the illness caused by the coronavirus, have several "atypical" symptoms, complicating efforts to ensure they get timely and appropriate treatment, according to physicians. COVID-19 is typically signaled by three symptoms: a fever, an insistent cough and shortness of breath. But older adults — the age group most at risk of severe complications or death from this condition — may have none of these characteristics.

Instead, seniors may seem "off" — not acting like themselves — early on after being infected by the coronavirus. They may sleep more than usual or stop eating. They may seem unusually apathetic or confused, losing orientation to their surroundings. They may become dizzy and fall. Sometimes, seniors stop speaking or simply collapse.

[REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Apr 2020 17:39:34 +0000
To: Janet Tobias; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Riding along tomorrow am

OK

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Janet Tobias <janet@ikanamedia.com>
Sent: Tuesday, April 28, 2020 12:46 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Subject: Riding along tomorrow am

Hi Tony and Patty:

Would it be ok to do the 6:45 am ride to NIH tomorrow? We would also get there early to do one more paper throw. And last night was great!

Janet

From: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Date: Sunday, April 26, 2020 at 4:30 PM
To: Janet Tobias <janet@ikanamedia.com>
Subject: RE: Quick question

My work with the Coronavirus Task Force and the large volume of incoming emails precludes me or my staff from answering each individual message. I would

encourage you to visit www.coronavirus.gov for the latest information and guidance related to COVID-19.

Thank you, and best regards.

Anthony S. Fauci, M.D.

From: Auchincloss, Hugh (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Apr 2020 15:50:24 +0000
To: NIAID OD AM
Subject: FW: Invitation from the Investment Community
Attachments: Letter of invitation_Dr. Anthony Fauci from UBS Investment Bank (1).pdf

I don't think so.

From: Elizabeth Haenle (b) (6) >
Sent: Tuesday, April 28, 2020 11:36 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Invitation from the Investment Community

Dear Dr. Fauci,

I am the co-founder of SAGE Worldwide, a global speaker and consulting company. I am reaching out on behalf of one of my partners, Robert Karofsky, Co-President of UBS Investment Bank, with an invitation to join the UBS Global response to Covid-19 in a live streaming moderated discussion on May 18. Alternatively your conversation could be pre-recorded to accommodate your busy schedule. At this critically important time in our nation's history, the investment community wants to help our nation fight Covid-19 and use our country's economic engine to find a cure and solutions for Covid-19. They also are thinking through how to help our nation's businesses going forward. Your expertise is important to this conversation.

By way of background, I served in the White House for eight years in the Bush Administration as the Social Secretary to Vice President Cheney. In that capacity, I had the privilege of curating a range of discussions with global thinkers and thought leaders on the world's most pressing topics. At SAGE, we bring that level of excellence to our business partners as we help curate discussions that have an impact on public awareness and investor sentiment, which is particularly important as the U.S. responds to Covid-19.

Additionally, (b) (6)

Participants at the UBS Global Healthcare Conference provide critical funding to pharmaceuticals and healthcare research and are the businesses on the frontline of the Covid-19 healthcare response.

Attached please find an invitation from UBS with further details of the event. I welcome the opportunity to hear from you at your earliest convenience, and thank you for your important work and dedication to our country's well being over the course of your distinguished career and service at NIAID.

Warmest regards,
Elizabeth Haenle
Co-Founder, SAGE Worldwide
Phone: (b) (6)
Attachment 1

--
Elizabeth Haenle 戴丽翠

Co-founder and President

M: [REDACTED] (b) (6)

E: [REDACTED] (b) (6)

W: SAGEworldwide.com



This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. If you have received this email in error please notify the system manager. This message contains confidential information and is intended only for the individual named. If you are not the named addressee you should not disseminate, distribute or copy this e-mail. Please notify the sender immediately by e-mail if you have received this e-mail by mistake and delete this e-mail from your system. If you are not the intended recipient you are notified that disclosing, copying, distributing or taking any action in reliance on the contents of this information is strictly prohibited.

From: Auchincloss, Hugh (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Apr 2020 14:46:56 +0000
To: NIAID OD AM
Subject: FW: HIGH SCHOOL MUN CONFERENCE

For discussion

From: Dane Cohn (b) (6) >
Sent: Tuesday, April 28, 2020 10:44 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Barasch, Kimberly (NIH/NIAID) [C] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6) >; Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: HIGH SCHOOL MUN CONFERENCE

Dear Dr. Anthony Fauci,

My name is Dane Cohn, and I am an (b) (6). I have often listened to your inspiring words on the news and followed your assiduous work to help us through this pandemic. Our school participates in Model UN, an event in which high school students represent various countries in debates on international issues from the past and present. Colorado's final Model UN conference was canceled, so our school ((b) (6)) decided to host an online conference for the whole state of Colorado and beyond. Our team would like to formally invite you to give a short address (be it pre-recorded or live online) to the students during our opening ceremony.

We hope that our conference will inspire the youth of our nation and the world to stand up and fight for our future rather than resign their aspirations to lockdown. We host this conference because we see the importance of keeping our academic passions going while staying safe within the confines of our homes. We host this conference because we want to contribute to the fight against COVID-19 — money raised from our conference will go towards buying masks, food, and other resources for those who need it most.

This is why we ask you, a hero during this troubling time, to speak to the students of our conference, who not only include the youth of Colorado, but also the youth of our country and world. Any type of address would be greatly and wholeheartedly appreciated. If your address is pre-recorded, we would appreciate it if we could receive it by May 1st, as our conference is the morning of May 2nd. We believe you can bring true inspiration into our hearts and minds. We know you are very busy, but if it were at all possible to share with us even a short 2-3 minute pre-recorded greeting and message to the students participating in this Model UN conference, it would be truly inspirational. Thank you so much for your time, we hope to hear from you soon.

Most Respectfully,
Dane Cohn and the entire (b) (6) Model UN Team

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Apr 2020 11:25:09 +0000
To: Haskins, Melinda (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Please advise LHHS Hearing w/ Dr. Fauci -- Wednesday, May 6

8:30 AM would be good. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Haskins, Melinda (NIH/NIAID) [E] (b) (6) >
Sent: Tuesday, April 28, 2020 7:08 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Subject: RE: Please advise LHHS Hearing w/ Dr. Fauci -- Wednesday, May 6

Let me know when you'd like me to call please.

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Sent: Tuesday, April 28, 2020 7:04 AM
To: Haskins, Melinda (NIH/NIAID) [E] (b) (6) >
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Subject: Re: Please advise LHHS Hearing w/ Dr. Fauci -- Wednesday, May 6

Let us chat by phone this morning

On Apr 28, 2020, at 5:51 AM, Haskins, Melinda (NIH/NIAID) [E] <(b) (6)> wrote:

We do not know if the DeLauro hearing would be remote. The Senate HELP one would be in person with some form of social distancing.

Sent from my iPhone

On Apr 27, 2020, at 10:36 PM, Fauci, Anthony (NIH/NIAID) [E]
(b) (6) > wrote:

E should make sure that we schedule it at a time of day that does not conflict with the COS visit.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Sent: Monday, April 27, 2020 8:20 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Fwd: Please advise LHHS Hearing w/ Dr. Fauci -- Wednesday, May 6

This is the day of the VIP visit—whoever it is. VP or COS. Pls advise. And not sure if these are 1 person or not. I suspect remote right??

Sent from my iPhone

Begin forwarded message:

From: "Haskins, Melinda (NIH/NIAID) [E]"
(b) (6)
Date: April 27, 2020 at 8:10:52 PM EDT
To: "Conrad, Patricia (NIH/NIAID) [E]"
(b) (6) >
Cc: NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>, "Billet, Courtney (NIH/NIAID) [E]" (b) (6) >, "Harper, Jill (NIH/NIAID) [E]" (b) (6)
Subject: Please advise LHHS Hearing w/ Dr. Fauci -- Wednesday, May 6

Patty,

See below. Another hearing.

Thank you,
Melinda

Sent from my iPhone

Begin forwarded message:

From: "Hallett, Adrienne (NIH/OD) [E]"
(b) (6)
Date: April 27, 2020 at 7:57:36 PM EDT
To: "Haskins, Melinda (NIH/NIAID) [E]"

(b) (6)>, "Selgrade, Sara
(NIH/NIAID) [E]" < (b) (6)>,
"LaMontagne, Karen (NIH/OD) [E]"
(b) (6)>, "Higgins, Lauren
(NIH/OD) [E]" (b) (6)>
**Subject: Fwd: LHHS Hearing w/ Dr. Fauci --
Wednesday, May 6**

Guess they really are coming back.

Begin forwarded message:

From: "Steigleder, Stephen"
(b) (6)
>
Date: April 27, 2020 at 7:41:56 PM
EDT
To: "Hallett, Adrienne (NIH/OD) [E]"
(b) (6)>
**Subject: LHHS Hearing w/ Dr. Fauci -
- Wednesday, May 6**

Hi Adrienne,

I hope you're doing well.

I'm reaching out because Chair DeLauro would like to invite Dr. Fauci to a hearing next Wednesday, May 6, with the House LHHS appropriations subcommittee. The focus of the hearing, not surprisingly, would be COVID-19. Members of the subcommittee would very much like to hear from Dr. Fauci on anything related to COVID-19, but I think the main topics would be:

- Mitigation and Testing; and
- Progress on vaccines, therapeutics, and diagnostics, as well as necessary preparations to manufacture and disseminate a vaccine once it is ready.

Chair DeLauro is flexible about a starting time for the hearing on Wednesday, so she would be happy to accommodate a time that works for Dr. Fauci's schedule.

Please let me know as soon as possible, so we can plan accordingly.

Thanks so much,

Stephen

.....
Stephen Steigleder
House Appropriations Committee
Labor/HHS/Education Subcommittee

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Apr 2020 00:22:50 +0000
To: [REDACTED] (b) (6)
Subject: FW: Remdesivir--good news
Attachments: 20-0006_DSMB_primary_analysis_report_for_DMID.pdf

From: Erbeling, Emily (NIH/NIAID) [E] [REDACTED] (b) (6) >
Sent: Monday, April 27, 2020 8:05 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Subject: Remdesivir--good news

Tony,

[REDACTED] (b) (5)

Emily

Emily Erbeling, M.D., M.P.H.
Director, Division of Microbiology and Infectious Diseases
NIAID/NIH
5601 Fishers Lane
Rockville, MD 20852
Tel: [REDACTED] (b) (6)

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 22:56:59 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW:
Attachments: Brown et al submitted.pdf, NIH Presentation final.pptx, preprints202002.0147.v2 (1).pdf, Mosaheb et al 2020.pdf

Email from Dani Bolognesi.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: (b) (6)
Email: (b) (6)

From: Dani Bolognesi, Ph.D. (b) (6) >
Sent: Monday, April 27, 2020 6:09 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Barasch, Kimberly (NIH/NIAID) [C]
(b) (6)
Subject: FW:

Kimberly: Please see that this reaches Tony as per our call today.

TX in advance.

Dani

Hi Tony:

In advance of getting together with you and your team, I am forwarding a short presentation for you guys to look at. The key elements are follows:



We are prepared to discuss this with you and your team at any time that is convenient for you. As you may know, we are locked down here in the Research Triangle until May 15. If it makes sense, we could arrange a WebEx as an initial step.

Many thanks for the opportunity to share this with you!

All the very best,

Dani

(b) (6)

Best,

Dani

Sent from Dani Bolognesi

From: "Dani Bolognesi, Ph.D." (b) (6) >

Date: Monday, April 27, 2020 at 2:53 PM

To: "Matthias Gromeier, M.D." (b) (6)

Subject: Please review this draft email to Tony--TX

Matthias: Please review and edit the proposed email to Tony.

Dani

Hi Tony: In advance of getting together with you and your team, I am forwarding a short presentation for you guys to look at. The key elements are follows:



We are prepared to discuss this with you and your tea at any time that is convenient for you. As you may know, we are locked down here in the Research Triangle until May 15. If it makes sense, we could arrange a WebEX as an initial step.

All the best,

Dani

Best,

Dani

Sent from Dani Bolognesi

The information in this electronic mail is sensitive, protected information intended only for the addressee(s). Any other person, including anyone who believes he/she might have received it due to an addressing error, is requested to notify the sender immediately by return electronic mail, and to delete it without further reading or retention. The information is not to be forwarded to or shared unless in compliance with Duke Health policies on confidentiality and/or with the approval of the sender.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 22:17:19 +0000
To: Folkers, Greg (NIH/NIAID) [E]; NIAID OD AM
Subject: RE: COVID/Transportation Impacts

Ok. Let us discuss forwarding to CDC>

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)
Sent: Monday, April 27, 2020 6:15 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: RE: COVID/Transportation Impacts

this seems like CDC issue

They address some of the issues here:

What Rideshare, Taxi, Limo, and other Passenger Drivers-for-Hire Need to Know about COVID-19
<https://www.cdc.gov/coronavirus/2019-ncov/community/organizations/rideshare-drivers-for-hire.html>

Communication Toolkit for Transportation Partners to Inform Road Travelers Monday, April 27, 2020
<https://www.cdc.gov/coronavirus/2019-ncov/travelers/transportation-toolkit.html>

Cleaning and Disinfection for Non-emergency Transport Vehicles Tuesday, April 14, 2020
<https://www.cdc.gov/coronavirus/2019-ncov/community/organizations/disinfecting-transport-vehicles.html>

-----Original Message-----

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6) > On Behalf Of Fauci, Anthony (NIH/NIAID) [E]
Sent: Monday, April 27, 2020 6:05 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: FW: COVID/Transportation Impacts

-----Original Message-----

From: Anthony Foxx [REDACTED] (b) (6)>
Sent: Monday, April 27, 2020 4:39 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: COVID/Transportation Impacts

Dr. Fauci:

This is Anthony Foxx, immediate former US Transportation Secretary, and I greatly enjoyed our interactions (brief thoughts they were) during my time in the last Administration.

I write to request your help in advising the transportation community about how to manage through the present crisis, particularly as some areas are easing restrictions. I would welcome an opportunity to join you in a Q/A, which could be valuable for rideshare companies [REDACTED] (b) (6), transit agencies, airlines etc. I would think that a 10-15 minute chat would do wonders. That said, I know you are terribly busy and have so many things to do but would appreciate any opportunity to help you get important information out.

This could be pulled together rapidly and done within the next week or so.

Thanks for your attention to this matter. All my best,

Anthony.
Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 22:00:13 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Update - White House Coronavirus Task Force Meeting - 4.28.20

FYI

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

(b)(5) - PCP

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 21:57:57 +0000
To: Lusso, Paolo (NIH/NIAID) [E]
Subject: RE: Covid thrombi

Thanks, Paolo.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lusso, Paolo (NIH/NIAID) [E] (b) (6)
Sent: Monday, April 27, 2020 12:34 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Kovacs, Joseph (NIH/CC/CCMD) [E] (b) (6); Masur, Henry (NIH/CC/CCMD) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6) >
Subject: Re: Covid thrombi

Dear Tony,

I talked with Dr. Viecca this morning who shared additional information about his protocol. They started from the pathological observation that all patients dying of Covid-19 pneumonia had diffuse pulmonary microthrombosis. Since they detected almost exclusively white thrombi, they reasoned that they had to block platelet activation/aggregation, while heparin would be ineffective at that stage. Thus, they treated a first group of five critical patients with potent anti-aggregant therapy (Tirofiban/Aggrastat) and apparently in all of them the pO2 started to rise within less than 2 hours, they got off the ventilators and went on to full recovery. Viecca is an interventional cardiologist (b) (4)

(b) (6) I sent copy of his protocol and contact information to Joe.

Let me know if I can be of any further help. All the best,

Paolo

Paolo Lusso, M.D., Ph.D.
Chief, Section of Viral Pathogenesis
Laboratory of Immunoregulation
Bldg. 10, Rm. 6A11
NIAID, NIH
Bethesda, MD 20892

Phone: [REDACTED] (b) (6) (personal)

[REDACTED] (b) (6) (lab)

Fax: (301) 480-5291

E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 21:57:23 +0000
To: Collins, Francis (NIH/OD) [E] (b) (6)
Cc: Mascola, John (NIH/VRC) [E]
Subject: FW: Revised Slides
Attachments: Vaccine Development Slides Revised Draft 042720.pptx

Pleas respond for both of us. I already cc'd you on an email that I sent to John with a minor comment about slide #2.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Marks, Peter (b) (6)
Sent: Monday, April 27, 2020 1:14 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Collins, Francis (NIH/OD) [E] (b) (6)
Cc: Mascola, John (NIH/VRC) [E] (b) (6)>
Subject: Revised Slides

Dear Francis and Tony,

Apologize that the prior slides were too busy. John conveyed that message. Please see these versions that may be more along the lines that you are looking for. (b) (5)

Best Regards,
Peter

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 21:54:37 +0000
To: Schwetz, Tara (NIH/OD) [E]
Subject: RE: Flagging NIH Media Product for Release Tomorrow

You could play the role in the movie of my medical school girl friend, which would give you the possibility of working with Brad Pitt 😊

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Schwetz, Tara (NIH/OD) [E] (b) (6)
Sent: Monday, April 27, 2020 5:49 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: Flagging NIH Media Product for Release Tomorrow

Now, you also have the answer to who would play you in a movie! 😊

Tara A. Schwetz, PhD
Acting Director, NINR
Associate Deputy Director, NIH
A: Building 1, Room 138
P: (b) (6) | M: (b) (6)

From: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Date: Monday, April 27, 2020 at 5:46 PM
To: Tara Schwetz (b) (6)
Subject: RE: Flagging NIH Media Product for Release Tomorrow

Thanks, Tara. Pitt was amazing. One reviewer of the SNL show said that Pitt looked “exactly like me”. That statement made my year. 😊

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Schwetz, Tara (NIH/OD) [E] (b) (6)>
Sent: Monday, April 27, 2020 5:11 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Marston, Hilary (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Barasch, Kimberly (NIH/NIAID) [C] (b) (6) Myles, Renate (NIH/OD) [E] (b) (6); Walsh, Elizabeth (NIH/OD) [E] (b) (6)
Subject: Flaggering NIH Media Product for Release Tomorrow

Tony,

Please see below and attached a time-sensitive COVID-19 item for your awareness and sharing with the remainder of the Task Force, as appropriate. The plan is to release this tomorrow.

Item 1: Title: Rapid Acceleration of Diagnostics (RADx) Initiative

Activity Type: Funding of new research program

Summary: With a (b) (5) investment from federal stimulus funding, RADx initiative will infuse funding into early innovation technologies to speed development of rapid and widely accessible COVID-19 testing. At the same time, NIH will seek opportunities to move more advanced diagnostic technologies swiftly through the development pipeline toward commercialization and broad availability. As part of the initiative, NIH is urging scientists and inventors with a rapid testing technology to compete in a national COVID-19 testing challenge for a share of up to \$500 million over all phases for further development. The goal is to add tens of millions per month of accurate and easy-to-use tests to all Americans by Fall 2020.

Impact on COVID-19 Pandemic Response: RADx will accelerate the development, validation, and commercialization of innovative new testing methods that can be deployed in point-of-care and home settings. These technologies are urgently needed to guide and inform safe return to work, school, and life activities.

Office: National Institute of Biomedical Imaging and Bioengineering

Action Date: Solicitation announcement April 28, 2020

Type of Action: Research Program Award

Potential for Press Coverage: Mainstream Press

Press Release in Development?: Yes

Do let me know if you have any questions.

(Also, Brad Pitt?! Wow, that was a really nice shout out/thank you.)

Best,

Tara A. Schwetz, PhD

Acting Director, NINR

Associate Deputy Director, NIH

A: Building 1, Room 138

P: (b) (6) | M: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 21:48:46 +0000
To: Birx, Deborah L. EOP/NSC
Cc: Redd, Stephen (CDC/DDPHSIS/OD);Hahn, Stephen
Subject: Flagging NIH Media Product for Release Tomorrow
Attachments: 2020-04-27_COVID-19WeeklyReport_NIBIB OD_tas.docx

Deb:

As an FYI. This is an initiative from NBIB/NIH on development of POC diagnostics for SARS-CoV-2.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 21:39:57 +0000
To: Stover, Kathy (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: FOR ASF REVIEW: Draft PR re: SARS-CoV-2 incidence in children

Looks fine. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Stover, Kathy (NIH/NIAID) [E] (b) (6)>
Sent: Monday, April 27, 2020 4:57 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Subject: FOR ASF REVIEW: Draft PR re: SARS-CoV-2 incidence in children

Hi Dr. Fauci,

Please find attached for your review a draft release about the launch of the Human Epidemiology and Response to SARS-CoV-2 (HEROS) study, which is intended to help determine the percentage of children infected with SARS-CoV-2 and the percentage of infected children who develop COVID. In addition, the study will examine whether rates of SARS-CoV-2 infection differ between children who have asthma or other allergic conditions and children who do not. Your draft quote is as follows:

“One interesting feature of this novel coronavirus pandemic is that very few children have become sick with COVID-19 compared to adults,” said NIAID Director Anthony S. Fauci, M.D. “Is this because children are resistant to infection with SARS-CoV-2, or because they are

infected but do not develop symptoms? The HEROS study will help us begin to answer these and other key questions.”

Thanks much,
Kathy

Kathy Stover
Branch Chief
News and Science Writing Branch
National Institute of Allergy and Infectious Diseases (NIAID)
Office of Communications and Government Relations
National Institutes of Health/HHS
31 Center Drive, Room 7A17E
Bethesda, MD 20892
Phone: (b) (6)
E-mail: (b) (6)
NIAID Media Line: (301) 402-1663

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 21:04:24 +0000
To: Auchincloss, Hugh (NIH/NIAID) [C] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E]; Jean W Pape
Subject: (b) (4)
Attachments: (b) (4)

Hugh:

(b) (6), (b) (4)

(b) (6) Please take care of it.

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: (b) (6)
Sent: Monday, April 27, 2020 3:01 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: (b) (4)

Tony,

(b) (4), (b) (6)

Best,

Bill

JEAN WILLIAM PAPE, MD

Howard and Carol Holtzmann Professor of Clinical Medicine,
Center for Global Health, Division of Infectious Diseases, Department of Medicine,
Weill Cornell Medical College, New York, New York, USA
402 East 67th Street, New York, NY 10065
Tel (Office) [REDACTED] (b) (6)

Director,
Les Centres GHESKIO,
33, Blvd. Harry Truman, Port-au-Prince, Haïti.
Tel (Office): [REDACTED] (b) (6)
Voip: [REDACTED] (b) (6)

From: Conrad, Patricia (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 16:09:04 +0000
To: NIAID OD AM
Subject: FW: The National Organization of Italian Americans in Film & Television (NOIAFT) - Interview Request

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[REDACTED] (b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Taylor Taglianetti <taylor@noiaft.org>
Sent: Monday, April 27, 2020 12:03 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Cc: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Subject: The National Organization of Italian Americans in Film & Television (NOIAFT) - Interview Request

Dear Dr. Fauci,

I hope this email finds you well. My name is Taylor Taglianetti and I am the founder of the National Organization of Italian Americans in Film & Television (NOIAFT).

Our organization is so very proud of the work you are doing for our country and sends tremendous thanks for the hope and reassurance you have instilled during these trying times.

It would be an honor to conduct a short interview with you. Our organization includes many young Italian Americans breaking into the entertainment industry and with the coronavirus dramatically impacting our field, I'd love to ask you a few questions about what the future of the entertainment business looks like. We'd be happy to send the questions in advance for your approval. If you don't have time for a phone call, the questions can be answered via email at your leisure.

Thank you for your time and consideration.

Sincerely,


Taylor Taglianetti

Founder, *The National Organization of Italian Americans in Film & Television (NOIAFT)*


(347) 686-4968

www.noiaft.org


taylor@noiaft.org











From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 14:19:38 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Media query: CNN, re: ASF's NAS web briefing on Saturday

I was referring only to animal (macaque) models. I never said that it looked good in humans. Human clinical trials are ongoing to answer that question. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Monday, April 27, 2020 9:30 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Fwd: Media query: CNN, re: ASF's NAS web briefing on Saturday

Pls advise

Sent from my iPhone

Begin forwarded message:

From: "Leifman, Laura (NIH/NIAID) [E]" (b) (6) >
Date: April 27, 2020 at 9:27:13 AM EDT
To: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6) >, NIAID FOG
<fog@niaid.nih.gov>
Cc: NIAID COGCORE <COGCORE@mail.nih.gov>, NIAID Media Inquiries
<mediainquiries@niaid.nih.gov>
Subject: Media query: CNN, re: ASF's NAS web briefing on Saturday

Elizabeth Cohen

CNN

Elizabeth.Cohen@turner.com

Topic: Statement by ASF during Saturday NAS web briefing

Deadline: urgent

Hi Patty,

Elizabeth would like to clarify something that Dr. Fauci apparently said about remdesivir during his NAS web briefing on Saturday. The transcribed segment of the talk that she is focused on says:

“Remdesivir is the one that’s gotten the most publicity. It is interesting that if you look at it in a prophylactic therapeutic model in MERS coronavirus infection, it looked pretty good. There was clinical benefits just reported a couple of weeks ago of SARS coronavirus 2 in rhesus macaques.”

She wants to clarify what Dr. Fauci meant by looking at remdesivir “in a prophylactic therapeutic model in MERS”—whether this means in an animal model or something else. It sounds like that phrase is referring to the RML study in which remdesivir successfully prevented disease in MERS-infected rhesus macaques, as reported in the Feb. 13 NIAID media availability pasted below. Is that correct?

Best,

Laura

Remdesivir Prevents MERS Coronavirus Disease in Monkeys

Results Support Testing Antiviral Against 2019 Novel Coronavirus

February 13, 2020

The experimental antiviral remdesivir successfully prevented disease in rhesus macaques infected with Middle East respiratory syndrome coronavirus (MERS-CoV), according to a new study from National Institutes of Health scientists. Remdesivir prevented disease when administered before infection and improved the condition of macaques when given after the animals already were infected.

The new report from NIH’s National Institute of Allergy and Infectious Diseases (NIAID) appears in the *Proceedings of the National Academy of Sciences*.

MERS-CoV is closely related to the 2019 novel coronavirus (SARS-CoV-2, previously known as 2019-nCoV) that has grown to be a global public health emergency since cases were first detected in Wuhan, China, in December.

Remdesivir has previously protected animals against a variety of viruses in lab experiments. The drug has been shown experimentally to effectively treat monkeys infected with Ebola and Nipah viruses. Remdesivir also has been investigated as a treatment for Ebola virus disease in people.

The current study was conducted at NIAID’s Rocky Mountain Laboratories in Hamilton, Montana. The work involved three groups of animals: those treated with remdesivir 24

hours before infection with MERS-CoV; those treated 12 hours after infection (close to the peak time for MERS-CoV replication in these animals); and untreated control animals. The scientists observed the animals for six days. All control animals showed signs of respiratory disease. Animals treated before infection fared well: no signs of respiratory disease, significantly lower levels of virus replication in the lungs compared to control animals, and no lung damage. Animals treated after infection fared significantly better than the control animals: disease was less severe than in control animals, their lungs had lower levels of virus than the control animals, and the damage to the lungs was less severe.

The scientists indicate that the promising study results support additional clinical trials of remdesivir for MERS-CoV and COVID-19, the disease that SARS-CoV-2 causes. Several clinical trials of remdesivir for COVID-19 are under way in China, and other patients with COVID-19 have received the drug under a compassionate use protocol.

The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services, also provided support for this study. Gilead Sciences, Inc., developed remdesivir, also known as GS-5734, and collaborated in the research.

MERS-CoV emerged in Saudi Arabia in 2012. Through December 2019, the World Health Organization had confirmed 2,499 MERS-CoV cases and 861 deaths (or about 1 in 3). Because about one-third of MERS-CoV cases spread from infected people being treated in healthcare settings, the scientists suggest that remdesivir could effectively prevent disease in other patients, contacts of patients, and healthcare workers. They also note the drug might help patients who are diagnosed with MERS or COVID-19 if given soon after symptoms start.

ARTICLE:

E de Wit *et al.* Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. *PNAS* DOI: 10.1073/pnas.1922083117.

WHO:

NIAID Director Anthony S. Fauci, M.D., and Emmie de Wit, Ph.D., a principal investigator in NIAID's Laboratory of Virology, are available to comment on this study.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 14:11:59 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Coronavirus Antigen Microarray

Please take a look and handle.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Anderson, Cassandra (NIH/NIDDK) [E] (b) (6) >
Sent: Monday, April 27, 2020 8:17 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: FW: Coronavirus Antigen Microarray

Good morning Dr. Fauci,

I work in NIDDK in bldg. 50 in the Laboratory Endocrinology and Receptor Biology.

Thank you for all the information you have provided to our nation. I also want to say you are doing a terrific job in handling the COVID-19 virus, without you and your staff I don't know where our country would be.

I received the email below this morning from Jiang Yufei from Sino Biological. Not sure why I was sent this email, but I thought of you and your staff. Please see the email below.

Thank you again for all that you are doing to help keep us safe!

Stay safe!

Cassandra Anderson
Administrative Professional
Bldg. 50 Room 4133
301-402-7845

From: Yufei Jiang <yufei.jiang@sinobiological.info>
Sent: Monday, April 27, 2020 8:04 AM
To: Anderson, Cassandra (NIH/NIDDK) [E] (b) (6)>
Subject: Coronavirus Antigen Microarray

Hi Cassandra,

Happy Day! I am excited to let you know that Sino Biological just released Coronavirus antigen Microarray (CoVAM) which belongs to our Sinommune™ Multiplex Antigen Microarray product line. You may get more details from the following link:

<https://www.sinobiological.com/research/virus/coronavirus-array>

Currently the standard pre-printed CoVAM array is sold in the unit of slide, 16 arrays/slide. In each array there are 65 antigens related to the viruses that can cause upper respiratory tract infections including the most recent SARS-CoV-2. The list price is \$3,200/slide. Please contact me for how to place the order if you are interested or need more information.

So far, this array has mainly been used for two purposes: 1) Sero-surveillance studies of COVID-19 infection, and 2) Evaluating antibody reactivity in animals (monkeys and mice) after vaccination. Please be advised that our array is for research use only (RUO), not for the diagnostic purpose which needs the FDA approval.

After you run the samples on the slide, you may read the slide on the following compatible machines:

<https://www.innopsys.com/en/lifesciences-products/microarrays/innoscan>

<https://www.moleculardevices.com/products/additional-products/genepix-microarray-systems-scanners#ref>

<https://www.agilent.com/en/product/cgh-cgh-snp-microarray-platform/cgh-cgh-snp-microarray-scanners-equipment/surescan-microarray-scanner-228493>

Thanks.

-Yufei

Yufei Jiang, PhD

Manager, NY, MD, DC, VA
Sales & Business Development
Sino Biological US Inc.
1400 Liberty Ridge Dr., Suite 101
Wayne, PA 19087
Cell: (b) (6)
Email: yufei_jiang@sinobiological.com
www.sinobiological.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 14:11:06 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Otto e Mezzo - Italian Show

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Torchia Patrizia <Patrizia.Torchia@la7.it>
Sent: Monday, April 27, 2020 8:05 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Otto e Mezzo - Italian Show

Dear Mr. Fauci,

I'm Patrizia Torchia, I'm a journalist and I am a member of the team on the Italian show *Otto e Mezzo*, hosted daily by journalist Lilli Gruber on La7 channel.

I'm reaching out to invite you in our show. Mrs. Gruber would be honored to have you, Dr. Fauci explore in more depth the challenges Coronavirus has forced the world to face. Can make this happen?

Below is Lilli Gruber's bio and a brief description of the show.

WHO:

Lilli Gruber is the editor-in-chief and host of Italy's most influential political daily talk show, "Otto e mezzo", airing on prime-time on La7 TV. She's received Italy's most prestigious journalism awards for her work and was the first woman to ever conduct the prime-time News broadcast in Italy (RAI TV, 1987). As a foreign correspondent she covered most of last 30 years' major world events, from the fall of the Berlin wall to 9/11 to the Iraq war. Beside her television work, Ms. Gruber wrote eleven bestseller books including "Eredità", which was top seller for 20 weeks and ran 14 reprints. In 2004, Ms. Gruber

won a head-to-head campaign against Silvio Berlusconi by a large margin of votes and was elected to the European Parliament. There, among other appointments, she was the Head of the EU Delegation to the Gulf States and Yemen and a member of the EU Delegation to Iran.

“Otto e mezzo”

Italy’s most influential political daily talk show shown on prime-time on La7 TV. Through interviews with elected political figures and candidates for office, commentators, and journalists, the show focuses on international political news and economy with a special focus on Italy and Europe. Beginning in 2008 “*Otto e Mezzo*” became Lilli Gruber’s way to keep her commitment to holding those in power accountable by asking questions and touching on topics citizens are curious about. **Otto e Mezzo** airs Monday to Saturday from 8:35pm to 9:10pm. Within this time-frame Paolo Pagliaro’s news column “Il Punto” stands out for accuracy and thoughtfulness by pulling the thread on the highest rated issues in an agenda. During the current season Otto e Mezzo has become Italy’s most watched political talk show reaching an average of 7.3% of share with 2.5 million viewers per day.

Production location(s): La7 studios, via Umberto Novaro 32, Rome, Italy

Presented by: Lilli Gruber

Original network: La7

Executive producers: Stefania Bucciarelli

Directed by: Lorenzo Fontana

www.live.la7.it

www.ottoemezzo.la7.it

Twitter: @OttoemezzoTW)

Facebook: OttoemezzoLa7)

Thank you in advance for the considering. Looking forward to hearing from you.

Patty Torchia

Otto e Mezzo

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 14:08:24 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Fauci and PayPal

Not really.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Monday, April 27, 2020 9:54 AM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: FW: Fauci and PayPal

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept

liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fetalvo, Ninio J. EOP/OVP [REDACTED] (b) (6)
Sent: Monday, April 27, 2020 9:51 AM
To: Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: FW: Fauci and PayPal

FYI—Defer to you on this.

From: Miller, Amanda <amanmiller@paypal.com>
Sent: Monday, April 27, 2020 9:18 AM
To: Fetalvo, Ninio J. EOP/OVP [REDACTED] (b) (6)
Cc: Walters, Lindsay <Lindsay.Walters@edelman.com>
Subject: [EXTERNAL] Re: Fauci and PayPal

Hi Ninio,

We are wondering if Dr. Fauci would like to have a taped Skype conversation with PayPal CEO and President Dan Schulman to talk about safety measures, health and science tied to COVID-19. We would air the conversation during a global employee all hands to our 23,000 employees and then we could syndicate parts of it externally on our social channels.

Thanks for any help in reaching Fauci's team.

Thanks,
Amanda

Amanda Christine Miller
Senior Director, Corporate Communications
408.219.0563
[@PayPalNews](#)


From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 14:07:40 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: RE: [REDACTED] (b) (4)

Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lerner, Andrea (NIH/NIAID) [E] [REDACTED] (b) (6)>
Sent: Monday, April 27, 2020 10:05 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: Re: [REDACTED] (b) (4)

I will make sure they get a response!

From: "Fauci, Anthony (NIH/NIAID) [E]" [REDACTED] (b) (6)>
Date: Sunday, April 26, 2020 at 8:43 PM
To: "Lerner, Andrea (NIH/NIAID) [E]" [REDACTED] (b) (6)>
Subject: FW: Update: [REDACTED] (b) (4)

Please respond to this person. Thanks.

From: Kircheis Dr. Ralf <RKircheis@syntacoll.de>
Sent: Wednesday, April 22, 2020 9:41 AM
To: Coomes, Stephanie (NIH/NIAID) [E] [REDACTED] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Cc: [REDACTED] (b) (6); Kircheis Dr. Ralf <RKircheis@syntacoll.de>
Subject: Update: [REDACTED] (b) (4)
Importance: High

Dear Dr. Fauci,
dear Dr. Coomes,

thank you for your reply from 13. April with the notice that the information has been shared with NIAID's COVID-19 research team.

Has the project already been initially evaluated by the team?

Are there any questions or need for additional information?



Looking forward to hearing from you.

Kind regards,

Ralf

Mit freundlichen Grüßen / Kind regards

Dr. Ralf Kircheis

Director R&D

Research & Development

Mail: RKircheis@syntacoll.de

Phone: +49 9441 686048

syntacoll

Syntacoll GmbH, Donaustrasse 24, D-93392 Saarl. d. Donau

Tel: +49 9441 / 68 60 0, Fax: +49 9441 / 68 60 30

Handelsregister: Amtsgericht Regensburg - HRB 1612

USt-IdNr. DE 128580796

Geschäftsführerin: Dr. Alexandra Dietrich

Unsere Hinweise zum Datenschutz, insbesondere zu den Ihnen zustehenden Rechten, finden Sie unter

www.syntacoll.de/datenschutz

Von: Coomes, Stephanie (NIH/NIAID) [E] (b) (6)]

Gesendet: Montag, 13. April 2020 02:37

An: Kircheis Dr. Ralf <RKircheis@syntacoll.de>

Betreff: RE: (b) (4), (b) (5)

Dear Dr. Kircheis,

Thank you for your recent email to Dr. Anthony Fauci. Your message was forwarded to the Division of Microbiology and Infectious Diseases (DMID) at the National Institute of Allergy and Infectious Diseases (NIAID). As a member of DMID's Office of Scientific Coordination and Program Operations, I am pleased to respond.

I want to thank you for reaching out to share this information and let you know that your message has been shared with NIAID's COVID-19 research team.

Sincerely,
Stephanie

Stephanie M. Coomes, Ph.D.
Health Scientist Administrator
Office of Scientific Coordination and Program Operations
Division of Microbiology and Infectious Diseases
National Institute of Allergy and Infectious Diseases
National Institutes of Health
5601 Fishers Lane, Room 7G68
Rockville, MD 20892

(b) (6)

(b) (6)

Disclaimer: The information in this email and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the originally intended recipient. If you have received this email in error, please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of NIAID by one of its representatives.

From: Kircheis Dr. Ralf <(b) (6)>

Sent: Wednesday, April 8, 2020 2:49 AM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Billet, Courtney (NIH/NIAID) [E]

(b) (6)>; NIAID Ocpostoffice (NIH/NIAID) <OCPOSTOFFICE@niaid.nih.gov>

Cc: Fischer, Elizabeth (NIH/NIAID) [E] (b) (6)>; Foster, Erin (NIH/NIAID) [E]

(b) (6) Foster, Sarah (NIH/NIAID) [E] (b) (6)>; Vasilenko, Olga

(NIH/NIAID) [E] (b) (6)>; Vasquez, Aurelio (NIH/NIAID) [E]

(b) (6)>; Vostal, Alexander (NIH/VRC) [F] (b) (6)>; Vazquez-

Maldonado, Nancy (NIH/NIAID) [E] (b) (6)>; Austin, James (NIH/NIAID) [E]

(b) (6)>; Agulto, Liane (NIH/NIAID) [E] (b) (6); Deckhut, Alison

(NIH/NIAID) [E] (b) (6) Kircheis Dr. Ralf <RKircheis@syntacoll.de>

Subject: WG: [REDACTED] (b) (4), (b) (5)

Importance: High

[REDACTED] (b) (4), (b) (5)

Dear Dr. Fauci,
dear Madams/Sirs,

I want to bring to your attension some potentially important experimental data and a new proposal for treatment of COVID-19 patients with acute respiratory distress syndrome and organ failure. Sorry for the broad distribution but I wanted to make sure that my message reaches you.

[REDACTED] (b) (4), (b) (5)

Please forward this mail to the colleagues you consider relevant for evaluation, discussion and consideration for your clinical strategy for COVID-19.

Please let me know if additional informations are necessary.

To my person: I have MD PhD degree and have many years experience in pharmaceutical development (Boehringer Ingelheim), Biotech (Igeneon, Aphton, Virologik GmbH) (for reference see also PubMed Kircheis r) currently leading R&D activities at Syntacoll (part of Innocoll). I am providing this information personally in order to help to find a treatment for COVID-19 patients.

Looking forward to getting feedback from you,


With kind regards,

Ralf Kircheis (MD PhD)

(b) (6)

rkircheis@syntacoll.de

(b) (6)



Mit freundlichen Grüßen / Kind regards

Dr. Ralf Kircheis

Director R&D

Research & Development

Mail: RKircheis@syntacoll.de

Phone: +49 9441 686048

syntacoll

Syntacoll GmbH, Donaustrasse 24, D-93242 Saal a. d. Donau
Tel: +49 9441 / 68 60 0, Fax: +49 9441 / 68 60 30
Handelsregister: Amtsgericht Regensburg - HRB 3612
USt-IdNr. DE 128580796

Geschäftsführerin: Dr. Alexandra Dietrich

Unsere Hinweise zum Datenschutz, insbesondere zu den Ihnen zustehenden Rechten, finden Sie unter
www.syntacoll.de/datenschutz







From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 12:33:44 +0000
To: Jeremy Farrar
Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Thanks, Jeremy. I saw the report in the Post from Saturday. These children had mostly respiratory disease and diarrhea. I will check with the docs at DC Children's Hospital about the presence of "multisystem inflammatory state". This could just be the advanced stage of their disease compatible with advanced SARS-COV-2

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeremy Farrar (b) (6)
Sent: Monday, April 27, 2020 7:38 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Dzau, Victor J. <VDzau@nas.edu>; George GAO (b) (6)>
Cc: Richard Hatchett (b) (6);
(b) (6); Hannon, Emma <EHannon@nas.edu>; Conrad, Patricia (NIH/NIAID) [E] (b) (6); Teresa Miller de Vega (b) (6); (b) (6); Rebeka Yasmin - CEPI (b) (6); ben.tinker@cnn.com; Amanda.Sealy@cnn.com; Neel.Khairzada@turner.com; Tia.Miller@turner.com; (b) (6) McGinnis, J. Michael <MMcGinnis@nas.edu>; (b) (6) Mun, Jenny <JMun@nas.edu>; (b) (6) Redfield, Robert R. (CDC/OD) (b) (6)>
Subject: Re: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Thanks Tony – have asked for that and will share as soon as I can.

I believe there have been reports in the Washington Post.

https://www.washingtonpost.com/local/new-dc-hospital-numbers-suggest-kids-do-face-some-risk-of-coronavirus-hospitalization/2020/04/25/5e78c268-86fe-11ea-878a-86477a724bdb_story.html

From: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>

Date: Monday, 27 April 2020 at 12:36

To: Jeremy Farrar <(b) (6)>, Victor Dzau <VDzau@nas.edu>, George Gao <(b) (6)>

Cc: Richard Hatchett <(b) (6)>

"Hannon, Emma" <EHannon@nas.edu>, "Conrad, Patricia (NIH/NIAID) [E]" <(b) (6)>, Teresa de Vega <(b) (6)>, Rebeka Yasmin - CEPI <(b) (6)>

"ben.tinker@cnn.com" <ben.tinker@cnn.com>, "Amanda.Sealy@cnn.com" <Amanda.Sealy@cnn.com>, "Neel.Khairzada@turner.com" <Neel.Khairzada@turner.com>, "Tia.Miller@turner.com" <Tia.Miller@turner.com>

"McGinnis, J. Michael" <MMcGinnis@nas.edu>, "Mun, Jenny" <JMun@nas.edu>, "Redfield, Robert R. (CDC/OD)" <(b) (6)>

Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Jeremy:

Thanks for the heads up. Is there any more detailed description of the precise clinical manifestations? They describe a "multisystem inflammatory state". It is vasculitis or anything more specific? Could be an infectious agent that has nothing to do with SARS-CoV-2 infection even though some children are circumstantially infected with SARS-CoV-2 or it could be a post-SARS-CoV-2 inflammatory syndrome, perhaps a Kawasaki syndrome-like disease. Please keep me informed if you hear any further information.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeremy Farrar (b) (6) >

Sent: Monday, April 27, 2020 7:13 AM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Dzau, Victor J. <VDzau@nas.edu>; George GAO (b) (6) >

Cc: Richard Hatchett (b) (6)

(b) (6) Hannon, Emma <EHannon@nas.edu>; Conrad, Patricia (NIH/NIAID) [E] (b) (6) Teresa Miller de Vega (b) (6); (b) (6); Rebeka Yasmin - CEPI (b) (6); <ben.tinker@cnn.com>; <Amanda.Sealy@cnn.com>; <Neel.Khairzada@turner.com>; <Tia.Miller@turner.com>; (b) (6); McGinnis, J. Michael <MMcGinnis@nas.edu>; (b) (6); Mun, Jenny <JMun@nas.edu>; (b) (6)

Subject: Re: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

To be aware of – news over night so a huge amount of uncertainty – important for COVID19 now, and a potential concern for how we view immunity, protection, post-infectious immunopathology.

<https://www.hsj.co.uk/acute-care/exclusive-national-alert-as-coronavirus-related-condition-may-be-emerging-in-children/7027496.article>

<https://t.co/Bj6YHLJ8zi>

From: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) >

Date: Sunday, 26 April 2020 at 19:52

To: Victor Dzau <VDzau@nas.edu>, George Gao (b) (6) >

Cc: Jeremy Farrar (b) (6) >, Richard Hatchett (b) (6)

(b) (6) "Hannon, Emma" <EHannon@nas.edu>, "Conrad, Patricia (NIH/NIAID) [E]" (b) (6) >, Teresa de Vega (b) (6) >, Rebeka Yasmin - CEPI (b) (6) >, "ben.tinker@cnn.com" <ben.tinker@cnn.com>, "Amanda.Sealy@cnn.com" <Amanda.Sealy@cnn.com>, "Neel.Khairzada@turner.com" <Neel.Khairzada@turner.com>, "Tia.Miller@turner.com" <Tia.Miller@turner.com>, (b) (6) "McGinnis, J. Michael" <MMcGinnis@nas.edu>,

(b) (6)>, "Mun, Jenny" <JMun@nas.edu>,
(b) (6)>

Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

It was a real pleasure to join all of you on this important session. Many thanks for inviting me.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Dzau, Victor J. <VDzau@nas.edu>

Sent: Saturday, April 25, 2020 3:59 PM

To: George GAO (b) (6)

Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6)

(b) (6); Hannon, Emma <EHannon@nas.edu>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)
(b) (6) ben.tinker@cnn.com;
Amanda.Sealy@cnn.com; Neel.Khairzada@turner.com; Tia.Miller@turner.com; (b) (6)
McGinnis, J. Michael <MMcGinnis@nas.edu>; (b) (6); Mun, Jenny
(b) (6); haja.bally@cepi.net

Subject: Re: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Dear Jeremy, Tony, Sanjay, George, Susan and Richard,

Thank you so much for your superb contributions. It was a spectacular session- a truly inspiring one. I am grateful to all of you.

Hope to see you soon.

Warmest regards,

Victor

On Apr 25, 2020, at 1:22 PM, George GAO [REDACTED] (b) (6) wrote:

I am waiting for being connected and will use slides which were sent to your office
George

发自我的iPhone

在 2020年4月24日, 01:49, Dzau, Victor J. <VDzau@nas.edu>
写道 :

Dear Jeremy, Tony, Sanjay, George, Susan, and Richard,

I'm really looking forward to this panel on COVID-19 at the NAS Annual Meeting on Saturday, April 25th at 2:00-3:30 pm ET. There is tremendous excitement and enthusiasm, and registration is through the roof.

I am sending this note to do a last minute check to see if there is anything you need from me. I also want to check whether you are planning to use slides. Will you be sending your slides to us to project or use the share screen feature to advance your own slides? Regardless, it would be helpful to me if you could send me your slides for my preparation.

I would greatly appreciate it if you would respond to this email.

Best,
Victor

PS, [REDACTED] (b) (6) my special assistant, will be sending you additional information about the session logistics shortly.

From: Dzau, Victor J. <VDzau@nas.edu>

Sent: Thursday, April 9, 2020 11:01 AM

To: Mun, Jenny <JMun@nas.edu>; [REDACTED] (b) (6)

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

Cc: [REDACTED] (b) (6) Hannon, Emma

<EHannon@nas.edu>; [REDACTED] (b) (6)

[REDACTED]
[REDACTED]

(b) (6); 'ben.tinker@cnn.com' <ben.tinker@cnn.com>;
'Amanda.Sealy@cnn.com' <Amanda.Sealy@cnn.com>;
'Neel.Khairzada@turner.com' <Neel.Khairzada@turner.com>;
'Tia.Miller@turner.com' <Tia.Miller@turner.com>; 'hujr@chinacdc.cn'

(b) (6)
Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information
regarding your Saturday April 25 participation

Dear all,

Thank you for agreeing to participate in a special late breaking session on the COVID-19 pandemic at the NAS annual meeting. Knowing how busy you are, I am sending this email in lieu of a call to prepare for the session.

As you know, this is a 90 minute session which aims to provide our audience with deeper insights into the latest developments in the COVID-19 response. I plan to hold an engaging discussion that covers the whole experience on dealing with this pandemic – from US to international, to preparedness and response, the biology of the virus, the state of diagnostic, treatment and vaccine development, and the importance of communication.

I will begin the session by providing brief (~3 min) opening remarks describing the circumstances of the pandemic. Then, I will introduce the panelists and you will each have 7 minutes to provide remarks. You may use a limited number of slides for illustration. I hope that each panelist will provide their own perspective and speak to the issues proposed below.

- Jeremy Farrar will discuss the global response to the pandemic, drawing from his experience as a global leader, the chair of the Scientific Advisory Group for the WHO's R&D Blueprint and as a member of the Global Preparedness Monitoring Board.
- Tony Fauci will discuss the US pandemic and provide his perspective as a member of the White House Coronavirus Task Force addressing the 2019–20 coronavirus pandemic.
- George Gao will discuss China's response to the pandemic and lessons learned for the rest of the globe.
- Susan Weiss will discuss the viral characteristics of SARS COV2 , insights into its pathobiology, immunity and development of a pan-CoV antiviral.
- Richard Hatchett will discuss the development of new vaccines and treatments against COVID-19.
- Sanjay Gupta will comment on the health system response to the pandemic and challenges related to communication and public engagement in responding to COVID-19.

Following remarks from each panelist, we will have a moderated discussion amongst ourselves – I will ask you a set of questions (15 mins) and then we will take questions from the web (25 mins). To prepare me to be your moderator, please send me any questions you would like me to ask you. For those of you who would like to have a prep call, please let me know and I will set it up.

Best,
Victor

From: Mun, Jenny

Sent: Wednesday, April 8, 2020 10:56 AM

To: [REDACTED] (b) (6)

Cc: Dzau, Victor J. ; [REDACTED] (b) (6) ; Mun, Jenny ; Hannon, Emma ;

[REDACTED] (b) (6)
[REDACTED] 'ben.tinker@cnn.com' ; 'Amanda.Sealy@cnn.com'
; 'Neel.Khairzada@turner.com' ; 'Tia.Miller@turner.com'

Subject: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Dear Speakers:

I am the logistical contact for the COVID-19 session that will be held as part of the Annual Meeting (online) program on Saturday, April 25 at 2:00 pm EDT. Thank you for agreeing to participate in this session. To help you with your planning, I have provided additional details below.

Please note that the session will be live webcast and the general public will also be able to watch the session. Video from the session will also be uploaded on the NAS YouTube channel (<https://www.youtube.com/user/theNASciences>) after the meeting. We will need to obtain signed speaker release forms for your participation in this session. I have attached the speaker release form for your review and submission. **Please return the signed speaker release form by Monday, April 13.**

Session speakers are asked to connect 30 minutes prior to the session start time (**by Saturday, April 25 at 1:30 pm EDT**) to allow the technical staff to check connections and prepare for the session. Details on how to connect will be sent before the meeting.

We will list you in our promotional materials as noted below. If this is incorrect, please let me know.

Anthony S. Fauci, Director, National Institute of Allergy and Infectious Diseases

Jeremy Farrar, Director, Wellcome Trust

George F. Gao, Director-General, Chinese Center for Disease Control & Prevention

Sanjay Gupta, Chief Medical Correspondent, CNN

Richard J. Hatchett, CEO, Coalition for Epidemic Preparedness Innovations

Susan R. Weiss, Professor of Microbiology, Perelman School of Medicine, University of Pennsylvania

Since many of us have moved to remote work environments, you may already be proficient with Zoom and other online meeting/collaboration applications. I am attaching a 'speaker guidelines' file in case you have any questions on how best to prepare for and stage your remote talk. We have technical staff available to help you become familiar with Zoom and its settings – such as “sharing your screen” (if you have slide presentations that need to be shown during your talk). We can arrange for a training session this week or next week. If you would like to schedule a session, please let me know as soon as possible.

Dr. Dzau's office will be in touch regarding the agenda for this session. If you have any other questions, please let me know.

Regards, Jenny

Jenny Mun
Membership Director
National Academy of Sciences
jmun@nas.edu

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 18:45:27 +0000
To: [REDACTED] (b) (6)
Subject: SNL review

OKAY, so here is something even better than having Brad Pitt portray me on SNL. It is a recent review of Pitt's performance in which the TV reviewer said :

"Kicking things off, the Oscar winner dropped jaws during the cold open with his monologue about President Donald Trump's recent (and concerning) comments about COVID-19.

"Good evening, I'm Dr. Anthony Fauci," Pitt began his monologue and looked nearly identical to the director of the National Institute of Allergy and Infectious Diseases."

Someone said Pitt looked "nearly identical" to me. Yikes!! 😊

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 18:37:57 +0000
To: Barnes, Freddie
Subject: RE: Appreciation

Freddie:

Many thanks for your kind note. It is much appreciated.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Barnes, Freddie <freddie.barnes@ncdps.gov>
Sent: Sunday, April 26, 2020 10:48 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Appreciation

Dr. Fauci I just wanted to express my profound appreciation to you for your work during this COVID-19 pandemic. I especially appreciate how you have spent considerable time and capital reaching out to the Black and brown communities. I saw excerpts of your snapchat with Will Smith and saw nearly all of your interview on the Breakfast Club. I regret I have to send an email to you re this matter. But this is the day we live in. Minority communities continue to be over-looked in crises and the impact of such crises on their respective communities. For you to be intentional about keeping the minority communities in the loop is commendable, especially since these communities will be absorbing the disproportionate share of the sicknesses and deaths coming from COVID-19.

Thanks for all of what you are doing in keeping the nation informed. Thanks for informing based on the facts, data, and truth.

Take care and "Cover your six."

Email correspondence to and from this address may be subject to the North Carolina Public Records Law and may be disclosed to third parties by an authorized state official.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 13:29:53 +0000
To: Adams, Jerome (HHS/OASH); (b) (6); Giroir, Brett
(HHS/OASH)
Cc: (b) (6)
Subject: RE: High touch points

(b) (5)

From: Adams, Jerome (HHS/OASH) (b) (6) >
Sent: Sunday, May 3, 2020 7:37 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; (b) (6); Giroir, Brett
(HHS/OASH) (b) (6) >
Cc: (b) (6)
Subject: Fwd: High touch points

Please see short thread below. Senator Young reached out to me about this and I forwarded to CDC. As I mention (b) (5)

(b) (5)

Thoughts?

Jerome

VADM Jerome Adams
20th US Surgeon General

Begin forwarded message:

From: "Adams, Jerome (HHS/OASH)" (b) (6) >
Date: May 3, 2020 at 7:32:46 AM EDT
To: "Jernigan, Daniel B. (CDC/DDID/NCIRD/ID)" (b) (6) >
Cc: "Schuchat, Anne MD (CDC/OD)" (b) (6)
Subject: Re: High touch points

Thank you.

(b) (5)

(b) (5)

Please keep me posted. And should I refer the senator to you or someone at CDC to close the loop?

Thanks!

J

VADM Jerome Adams
20th US Surgeon General

On May 2, 2020, at 7:08 PM, Jernigan, Daniel B. (CDC/DDID/NCIRD/ID)
(b) (6) > wrote:

ADM Adams:

Thanks for sending this. There has been a lot of guidance on disinfection and cleaning, notably some very recent collaborative work we have done with EPA (<https://www.cdc.gov/coronavirus/2019-ncov/community/reopen-guidance.html>). Attached are two documents focused on re-opening America with emphasis on cleaning and disinfection, including high-touch surfaces. Also below are a number of websites that address cleaning and disinfection which point out the importance of disinfecting high-touch locations like doorknobs. They give guidance how to clean them, but they don't address methods for using a paper towel or Kleenex to first turn the knob and then discard the towel. (b) (5)

Thanks
Dan.

Daniel B. Jernigan, MD MPH
Director, Influenza Division; HHS CDC Lead, FEMA-HHS COVID-19 Response
Captain, USPHS (RET)
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
1600 Clifton Rd NE, Atlanta, GA 30329
Phone (b) (6), Cell (b) (6)
(b) (6) www.cdc.gov/flu

<https://www.cdc.gov/coronavirus/2019-ncov/community/disinfecting-building-facility.html>

<https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/disinfecting-your-home.html>

<https://www.cdc.gov/coronavirus/2019-ncov/community/disinfecting-building-facility-H.pdf>

From: Adams, Jerome (HHS/OASH) (b) (6) >
Sent: Friday, May 1, 2020 5:35 PM
To: Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) (b) (6) >
Cc: Schuchat, Anne MD (CDC/OD) <(b) (6)>
Subject: High touch points

Dr. Jernigan,

I got a message from a Senator asking why we didn't have specific reopening recommendations for "high touch" points like door knobs/ handles/ elevator buttons. The Senator stated that [REDACTED] (b) (5)

[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED] I told him I'd follow up with CDC, (b) (5)

[REDACTED]

[REDACTED] Would appreciate your feedback on this.

Jerome

VADM Jerome Adams, MD, MPH

20th U.S. Surgeon General

<Reopening_America_Guidance.pdf>

<ReOpening_America_Cleaning_Disinfection_Decision_Tool.pdf>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 22:37:05 +0000
To: Hahn, Stephen;Debi Birx;Redfield, Robert R. (CDC/OD);Verma, Seema (CMS/OA)
Subject: RE: Serology Studies in Germany

Thanks, Steve!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Hahn, Stephen (b) (6) >
Sent: Thursday, April 30, 2020 6:34 PM
To: Debi Birx (b) (6) >; Redfield, Robert R. (CDC/OD) (b) (6),
Seema (CMS/OA) <(b) (6)>; Fauci, Anthony (NIH/NIAID) [E]
(b) (6)
Subject: Fwd: Serology Studies in Germany

Interesting information from Germany

From: Shuren, Jeff <(b) (6)>
Date: April 30, 2020 at 5:46:27 PM EDT
To: Hahn, Stephen <(b) (6)>, Shah, Anand (b) (6) >, Lenihan, Keagan
(b) (6) >, Guram, Jeet <(b) (6)>, Rom, Colin
(b) (6) >
Subject: Serology Studies in Germany

FYSA regarding serology studies being conducted in Germany, including status of tests to be used for those studies. This is the follow up to what I sent you last week. (b) (5)

(b) (5)

From: Hoshi, Ryan <[REDACTED] (b) (6)>

Sent: Thursday, April 30, 2020 3:17 PM

To: Shuren, Jeff [REDACTED] (b) (6)


Cc: Nalubola, Ritu [REDACTED] (b) (6); Louati, Claudia (FSN)* [REDACTED] (b) (6);

O'Leary, Brendan [REDACTED] (b) (6); Torres, Melissa A [REDACTED] (b) (6);

Stenzel, Timothy [REDACTED] (b) (6);

Subject: FW: PLEASE REVIEW >> Meeting Notes - Call with [REDACTED] (b) (5)

(b) (5)





Thank you,
Ryan

Ryan A. Hoshi, Ph.D.

International Policy Analyst | Center for Devices and Radiological Health | (b) (6) | phone
(b) (6) | mobile (b) (6)



Excellent customer service is important to us.

Please take a moment to provide feedback regarding the customer service you have received.

[click here for survey](#)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 14:14:36 +0000
To: Halkovich, Townshend Connie
Subject: RE: Appreciation to my hero--Dr. Fauci--our country's voice of reason in these unsettling, uncertain times--We NEED YOU!!!! Please don't leave us now when we need you most!!!

Connie:

Many thanks for your kind note. Much appreciated.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Halkovich, Townshend Connie (b) (6)
Sent: Monday, April 27, 2020 9:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Halkovich, Townshend Connie (FDA/OC) (b) (6)
Subject: RE: Appreciation to my hero--Dr. Fauci--our country's voice of reason in these unsettling, uncertain times--We NEED YOU!!!! Please don't leave us now when we need you most!!!

Where is Dr. Fauci?

I know where Dr. Fauci is—I saw him on SNL—remarkably he looked like Brad Pitt—except [to many of us] Dr. Fauci is better looking. Smile, wink *Why? We look with our hearts*
I remember someone asked Dr. Fauci [in jest] who would he like to represent him in a movie...Dr. F. said Brad Pitt. Well—Dr. F. Your dream suggestion came true. But, in many of our hearts—NO ONE can take the place of our beloved, well respected, honored Dr. Anthony Fauci!!!!

God Bless America, God Bless Dr. Fauci !!!

From: Halkovich, Townshend Connie <(b) (6)>
Sent: Friday, March 13, 2020 11:06 AM

To: 'anthony.fauci@nih.gov' (b) (6)
Cc: Halkovich, Townshend Connie <Constance.Halkovich@fda.hhs.gov>
Subject: Appreciation

Dear Dr. Fauci:

1st & foremost—please keep yourself healthy....get more rest than 3 hrs/night. 😊 Why? We need you!
THANK YOU for all your very informative updates. YOU are voice of reason...in time of coronavirus
fear...you give us hope...saying that action is what is needed...not fear!
You are someone we can be proud of...you provide service we can count on!!!!
God bless You & Your Family!!!

Warmest Regards from:

Connie Leigh Townshend Halkovich, Management Analyst, 410-867-0878,

#FDA/OIMT/DIO Proud: People & Service you can count on! 😊

(b) (6)

*My Wish 4 U: Peace, Love, Laughter —blessed 2 work with U ALL! Abe Lincoln: "folks are as happy as they choose 2 be"—B
happy all circumstances—Hope all well with you, yours—if not, pretend it is.*

FDA Mission: Responsible for protecting public health by ensuring safety, efficacy/security of human & vet. drugs, biol. products, med.
devices, our nation's food supply, cosmetics, & products that emit radiation.

DIO Mission: Provide excellent implementation, operation, maintenance of IT [equipment, services] to promote FDA's Public
Health Mission.

DIO Vision: Provide state-of-the-art IT services-inclusive of surrounding policy, planning, customer service, integration, &
oversight necessary to make the mission successful & sustainable.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 22:26:27 +0000
To: Folkers, Greg (NIH/NIAID) [E];Billet, Courtney (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E];Routh, Jennifer (NIH/NIAID) [E];Awwad, David (NIH/NIAID) [C]
Cc: NIAID OD AM
Subject: RE: ASF RE: Dr. Fauci video request: Public Service Recognition Week
Attachments: ASF public service recognition - with tracked edits -05-05-2020.docx



See minor tracked changes.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Sent: Tuesday, May 5, 2020 6:16 PM
To: Billet, Courtney (NIH/NIAID) [E] (b) (6) >; Stover, Kathy (NIH/NIAID) [E] <(b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6); Awwad, David (NIH/NIAID) [C] (b) (6) >
Cc: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: ASF RE: Dr. Fauci video request: Public Service Recognition Week

ASF –

Here is a short script for Public Service Recognition Week. We agreed to do a short video

ASF – can u tweak as needed?

David, could u record in some format that is easy? Cell phone or other I just learned they want by COB tomorrow

<< File: ASF public service recognition.docx >>

From: Seigfreid, Kim (NIH/OD) [E] (b) (6)>
Sent: Monday, April 27, 2020 4:30 PM
To: Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6)>
Cc: Fine, Amanda (NIH/OD) [E] (b) (6)>; Polimeni, Lydia (NIH/OD) [E] (b) (6)
Subject: Dr. Fauci video request: Public Service Recognition Week

Hi there,

Please see below. HHS is taking over the Partnership for Public Service IG account next week for Public Service Recognition Week. They asked if Dr. Fauci would be willing to do a short 30-second or less pre-recorded video thanking public servants for their work. It would be featured during the takeover, and also on NIH's other sm handles next week. It can be taken on a cell phone as sm does not require higher resolution. Let me know if you would like to accept or decline the request.

Many thanks,
Kim

Kim Seigfreid
Social Media Lead
NIH Office of Communications and Public Liaison
ph: (b) (6)
(b) (6)

From: Muhammad, Janell (HHS/ASPA) <(b) (6)>
Sent: Monday, April 27, 2020 4:10 PM
To: Seigfreid, Kim (NIH/OD) [E] (b) (6)>; Channer, Amber (OS/OASH) (b) (6)>; Foster, Timothy (OS/ASPA) (b) (6)>
Cc: Palczewski, Andrew (HHS/ASPA) <(b) (6)>; Pratt, Michael (OS/ASPA) <(b) (6)>; Sherman, Jennifer (HHS/OASH) (b) (6)
Wilker, Michael (HHS/ASPA) (b) (6); Dine, Brooke (HHS/ASPA) (b) (6)
Subject: Public Service Recognition Week

Hello All,

Hope everyone is holding up well!

OHR is taking over the Partnership for Public Service (PPS) Instagram account during Public Service Recognition Week (May 3-9, 2020). The OHR team has reached out about wanting to develop a senior leader "mashup" video —perhaps including the DepSec. T

They asked about the feasibility of this request. They also inquired about perhaps Dr. Fauci and the SG doing a pre-recorded video thanking public servants for their work.

I wanted to gather the troops so we can identify what all is being planned for this week of recognition and provide a POC for OHR if the request is feasible.

Happy to set up a call, if that is needed to discuss further.

Thanks,
Janell

Janell Muhammad

ASPA Digital Engagement (Team Lead)
U.S. Department of Health and Human Services

Email: (b) (6)

Office: (b) (6)

iPhone: (b) (6)

[HHS on Facebook](#) | [HHS on Twitter](#) | [HHS Latino](#)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 21:58:55 +0000
To: Adams, Jerome (HHS/OASH)
Subject: RE: Update on Sara Alert

What do you mean by [REDACTED] (b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Adams, Jerome (HHS/OASH) [REDACTED] (b) (6) >
Sent: Tuesday, May 5, 2020 2:49 PM
To: Birx, Deborah L. EOP/NSC <[REDACTED] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E]
[REDACTED] (b) (6) >
Subject: FW: Update on Sara Alert
Importance: High

[REDACTED] (b) (5)

Jerome

VADM Jerome Adams, MD, MPH
20th U.S. Surgeon General

From: Jarris, Paul [REDACTED] (b) (6) >
Sent: Friday, May 1, 2020 7:29 PM
To: Adams, Jerome (HHS/OASH) [REDACTED] (b) (6) >
Cc: Wright, Janet (HHS/OASH) [REDACTED] (b) (6)

Subject: Update on Sara Alert

Importance: High

Dear Jerome,

I hope you are well. Thank you for all you are doing to represent public health and our nation. It is very comforting knowing you are informing the nations COVID-19 response.

I wanted to give you an update on called Sara Alert, the software program I am leading at MITRE. Sara Alert is being provided free of any costs and deployed in state, tribal, and local health departments to support public health in contact tracing and active monitoring of individuals in isolation and quarantine. We are engaged with ASTHO, NACCHO, CSTE, and the application is hosted live on APHL's AIMS platform. Sara Alert officially launched on April 3 and is currently supporting multiple jurisdictions including Commonwealth of the Northern Mariana Islands, Danbury, CT, and the State of Arkansas. It is also being rolled out in Washington, Arizona, Pennsylvania, Virginia, Maine and Vermont. We are getting ready to launch in additional jurisdictions over the next couple of weeks.

We have recently responded to questions we were told came from the White House so I wanted to make sure you have background materials. I imagine you are the person that the President and Vice President would turn to for information. I am happy to arrange any briefing materials or demo that would be helpful for you to respond.

As I mentioned previously, **Sara Alert** is a standards-based, open source tool that automates the process of monitoring individuals exposed to or infected with COVID-19 (or any disease, it's configurable) – and will serve as an enduring national resource to contain disease. Sara Alert is free for use by public health organizations.

Best wishes to you. Stay healthy for all of us.

Paul

ABOUT SARA ALERT

In response to the COVID-19 pandemic, the MITRE Corporation, a not-for-profit that works in the public interest, developed **Sara Alert**, a standards-based, open source tool in partnership with national public health organizations. Sara Alert **automates the process of monitoring** individuals exposed to or infected with COVID-19 (or any disease, it's configurable) – and will serve as an **enduring national resource** to contain disease. **Sara Alert is free for use by public health organizations.**

- Sara Alert allows public health officials to import and enroll individuals (or households) at risk of developing or infected with COVID-19.
- Individuals enter their symptoms daily via web, text, email or phone, allowing public health officials to focus on high risk and non-reporting individuals.
- The web-based tool enables increased efficiency in tracking cases, leading to earlier containment of the virus and reduction of burden on public health resources.
- Sara Alert is a national system and allows transferal of monitorees across jurisdictions for tighter contact tracing.

Sara Alert launched on April 3 and **is now supporting multiple jurisdictions.**

Sara Alert YouTube Video: <https://youtu.be/IQxAuNsg-RA>

Paul E. Jarris, MD, MBA
Chief Medical Advisor
Health Transformation Center
MITRE Corporation

(b) (6)

(b) (6) Office

(b) (6) Mobile

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 17:45:26 +0000
To: Lane, Cliff (NIH/NIAID) [E]; Collins, Francis (NIH/OD) [E]
Cc: Lowy, Douglas (NIH/NCI) [E]; Mascola, John (NIH/VRC) [E]
Subject: RE: Gallo and OPV

(b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lane, Cliff (NIH/NIAID) [E] (b) (6) >
Sent: Sunday, May 3, 2020 1:22 PM
To: Collins, Francis (NIH/OD) [E] (b) (6) >
Cc: Lowy, Douglas (NIH/NCI) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Mascola, John (NIH/VRC) [E] (b) (6) >
Subject: Re: Gallo and OPV

Francis,

(b) (5)

Cliff

On May 3, 2020, at 12:55 PM, Collins, Francis (NIH/OD) [E] (b) (6) wrote:

Hi all,

I'm a bit at a loss to know how to respond to Bob Gallo. [REDACTED] (b) (5)

Francis

From: Gallo, Robert [REDACTED] (b) (6) >
Sent: Sunday, May 3, 2020 12:07 PM
To: Collins, Francis (NIH/OD) [E] [REDACTED] (b) (6)
Subject: RE: Your query to Dr. Kadlec

Dear Francis,

It was a pleasure to hear from you, and yes, it has been a long time since we met or even spoke. Moons ago I was set to write to you after reading your wonderful book, but I ended up instead speaking with others about it. I should add at this point that I did not quickly respond to your email of a few days ago because I simply missed it.

It is true that I strongly suggest that OPV be quickly (already it is not quickly) brought forward for induction of a strong innate immune response to prevent or markedly reduce SARS-CoV-2 infection and/or severity until the field obtains a proven safe and efficacious vaccine producing a long lasting, adaptive immunity. OPV is very safe (notably for OPV 1 and 3 as bOPV which we will use and completely safe in a vaccinated population), simple, cheap, rather obvious, yet unique among the massive number of vaccines many (maybe most) of which are the same or at least if not exactly the same aiming at the same mechanism (targeting the spike and searching for the putative correlate of neutralizing Abs.).

OPV should work for a few months and possibly longer. Also it should be working multiple times so I think could cover more than a few months, giving us time for a proven vaccine of adaptive immunity, which might be very long lasting as is hoped.

In the main the WHO comments are correct. Of course we sought and have letters of support from them as well as from many others. Though they are again supportive in their notes to you, there is one item that surprises me. They add that there was no clinical efficacy results as yet. They know or certainly should know that there is plenty of clinical data for this concept with BCG, OPV, and live Measles vaccine. Needless to say this is what turned me on during our regular Global Virus Network (GVN) conference calls. (Incidentally GVN is an organization I have thought of bringing to your attention. I think you would find it impressive and useful). I would be happy to share with you the clinical observations with OPV if you wish.

I would like to take a small diversion, but I suspect you are aware of these things. My colleagues and I respect the WHO because of its representation and because we have colleagues/friends there as well. However, sometimes bureaucracy of a massive degree leads to inaction or even much worse-- political expediency. I won't bother you with details of these unless you ask, but I had such experiences with HTLV-1 which we discovered in 1980 as the 1st human retrovirus and which cause not only the highest incidence of cancer (% of infections) of any virus and other fatal diseases as well but mainly in less developed countries (plus Japan) and again with HIV in 1984. Behavior was not beneficial. Perhaps it will be of relevance in the future because a few at WHO took a position to remove OPV (Sabin) in favor of IPV (Salk) in their polio eradication scheme. It was a huge failure. As my FDA collaborator, Konstantin Chumakov, says "Blessed be Bill Gates" because he saved OPV and saved the day and in so doing has produced a still better OPV.

There is indeed data also for BCG as well as live Measles though I know less of the latter. BCG is less available, requires injection, harder to make, not as safe, and we think unlikely to be as effective as OPV. Nonetheless, we favor its use too. The mechanisms will be similar.

You asked whether monkey trials are planned. For several reasons definitely not -- though we are planning some monkey experiments, but not large enough for "clinical" conclusions. The main reasons are: 1) cost; 2) that billions not thousands or millions have received OPV safely and in our collective view (and we know the studies pretty well) protection has been clinically shown; 3) In a pandemic we wished to move quickly (so far we must say that has not been achieved). A typical monkey vaccine study will take time, but 4) in this case it would be a huge amount of lost time as monkeys require great doses of polio for infection and monkeys have to be trained to drink their orange juice. It would be hard to imagine that such studies would even give us useful information.

On a final digression Francis I have had 36 years of on/off experiences with glycosylated spike proteins—their analyses immunologically and especially regarding use in vaccines and developing neutralizing Abs. I believe it will be a mistake to put most eggs in that basket. The risks: shortened antibody half life; 2) protection NOT correlating with neutralizing Abs; 3) sometimes hazards from them. Admittedly, they might work, but I trust and hope that not everything is going in this bag. If you wish to discuss this again I will be available.

Finally, I had no idea you were into vaccines or SARS-2 nor any part of CoVID-19 disease, but I am very happy to learn this.

Thanks.

Bob Gallo

From: Collins, Francis (NIH/OD) [E] (b) (6) >
Sent: Thursday, April 30, 2020 5:00 PM
To: Gallo, Robert (b) (6) >
Cc: Disbrow, Gary (OS/ASPR/BARDA) < (b) (6) >; Kadlec, Robert (OS/ASPR/IO) (b) (6) >; Tabak, Lawrence (NIH/OD) [E] < (b) (6) >; Shuy, Bryan (OS/ASPR/IO) (b) (6) >; Johnson, Robert (OS/ASPR/BARDA) (b) (6) >; Mascola, John (NIH/VRC) [E] (b) (6) >; Lane, Cliff (NIH/NIAID) [E] (b) (6) >
Subject: Your query to Dr. Kadlec

CAUTION: This message originated from a non UMB, UMSOM, FPI, or UMMS email system. Whether the sender is known or not known, hover over any links before clicking and use caution opening attachments.

Dear Bob,

It's been quite a while since we've chatted. Bob Kadlec asked me to respond to your query about the possible use of OPV to activate innate immunity and provide COVID-19 protection. Has this been tested in a non-human primate model? I note the recommendation below that says a clinical trial is planned – can you tell me more about that?

As you can imagine, we are all flat out on the vaccine development pathway!

Francis

The use of oral polio vaccine (OPV) to prevent SARS-CoV2 (Polio Eradication Campaign)

There is no evidence that oral poliovirus vaccine (OPV) protects people against infection with COVID-19 virus.

A clinical trial addressing this question is planned in the USA, and WHO will evaluate the evidence when it is available.

In the absence of evidence, WHO does not recommend OPV vaccination for the prevention of COVID-19. WHO continues to recommend OPV as part of essential immunization services to prevent poliomyelitis and as part of global polio eradication efforts.

There are experimental signals from various studies over the years that OPV has non-specific effects on the immune system. These effects have not been well characterized and their clinical relevance is unknown. Such non-specific effects may

not be limited to OPV, as other live vaccines have also been associated with non-specific protective effects (such as BCG vaccine against tuberculosis). Nonlive vaccines in contrast do not seem to have the same effects.

The exact mechanism of non-specific protection induced by live vaccines needs to be elucidated further. Clinical studies could begin immediately because the vaccines in question are licensed and have an excellent safety record. Clinical trials involving off-label use of various drugs licensed for other indications are currently underway. The existing scientific rationale suggests that the same should be done for OPV and other live vaccines. A study is currently being discussed with various partners and vaccine manufacturers, including the US FDA, the outcomes of which will be carefully assessed to determine potential use in the context of the spread of SARS-CoV2 until the time when specific vaccines and antiviral therapies are ready.

From: Kadlec, Robert (OS/ASPR/IO) (b) (6)
Sent: Thursday, April 30, 2020 10:28 AM
To: Gallo, Robert (b) (6); Collins, Francis (NIH/OD) [E]
<(b) (6); Tabak, Lawrence (NIH/OD) [E] (b) (6)>; Shuy, Bryan (OS/ASPR/IO) (b) (6)>
Subject: Re: Response

Dr Gallo thank you for your note and I appreciate you reaching out to me. I have copied Dr Collins and Dr Tabak to consider the ACTIV forum they have created to bring industry academia and government to consider scientific base approaches That you have described. Dr Collins has organized a vaccine group and I assess could be the best and fastest place to discuss your concept. I am sure they will connect with you soonest

Best

Bob Kadlec.

Sent from my iPhone

On Apr 30, 2020, at 10:02 AM, Gallo, Robert (b) (6) >
wrote:

Dear Dr. Kaldec,

I have not heard from you in over a week. You mentioned getting back to me in a day or two. Time is passing. I am asking you to look at OPV 1 plus 3 serotypes as a bivalent, completely safe vaccine with powerful stimulation of innate immunity lasting several weeks , which can be given a second or third time, and with a historical track record of

preventing other infections from entirely different RNA viruses (such as protecting against influenza). Therefore, it should be really helpful for some months, and I think get us past a second wave of SARS-CoV-2, and help people return to work safely. I don't understand delays or apparent lack of interest. Who can possibly be against this? If you hear of hypothetical problems we can show you that these are false. Just ask the questions, and we can give you the evidence.

However, no answer from you suggests no interest and must quickly make alternative pathways. I am though quite surprised and fear you are receiving "fake news" if you will pardon the expression. Some have been against this who defend their old and failed position on polio eradication with their promotion of the use of the inactivated polio virus vaccine. Please note that in the US between 1962 and 1985 we received (safely) the oral polio (OPV). Moreover, if vaccinated already there has not been a single case of a complication and BILLIONS have received it. No it will not last long as innate immunity is short lived, but we strongly believe that we can break the back of the SARS-CoV-2 spread. Also note that this is what Bill Gates is doing now in India and much of the Eastern hemisphere.

There are countries outside the US wanting to move fast on this. We are waiting for your reply.

Robert Gallo
Director, Institute of Human Virology,
Professor of Medicine and Professor of Microbiology,
UMB, School of Medicine, Baltimore,

And
Co-founder and International Science Advisor of the Global Virus
Network (GVN)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 15:17:01 +0000
To: Collins, Francis (NIH/OD) [E]; Mascola, John (NIH/VRC) [E]; Lane, Cliff (NIH/NIAID) [E]
Cc: Tabak, Lawrence (NIH/OD) [E]
Subject: RE: Response

Francis:

Thanks for the note. I will let Cliff speak for himself, [REDACTED] (b) (5)

[REDACTED] (b) (5)

[REDACTED] (b) (5) but I will let him speak for himself. We can discuss further if you wish.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Collins, Francis (NIH/OD) [E] (b) (6) >
Sent: Thursday, April 30, 2020 10:58 AM
To: Mascola, John (NIH/VRC) [E] (b) (6) >; Lane, Cliff (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Tabak, Lawrence (NIH/OD) [E] (b) (6) >
Subject: FW: Response

Hi John, Cliff, and Tony,

Ignore the silly part of the message below, where (b) (5)
(b) (5). But let me ask you guys whether (b) (5)
(b) (5)
(b) (5)

Francis

From: Collins, Francis (NIH/OD) [E]
Sent: Thursday, April 30, 2020 10:55 AM
To: Kadlec, Robert (OS/ASPR/IO) (b) (6)
Cc: Tabak, Lawrence (NIH/OD) [E] (b) (6) >; Shuy, Bryan (OS/ASPR/IO) (b) (6); Disbrow, Gary (OS/ASPR/BARDA) (b) (6) >; Johnson, Alfred (NIH/OD) [E] (b) (6)
Subject: RE: Response

Bob,

Dropping Bob Gallo from the thread, but adding Gary and Robert. (b) (5)
(b) (5)
(b) (5)
(b) (5) Please advise.

Francis

From: Kadlec, Robert (OS/ASPR/IO) (b) (6)
Sent: Thursday, April 30, 2020 10:28 AM
To: Gallo, Robert (b) (6) >; Collins, Francis (NIH/OD) [E] (b) (6); Tabak, Lawrence (NIH/OD) [E] (b) (6) >; Shuy, Bryan (OS/ASPR/IO) (b) (6)
Subject: Re: Response

Dr Gallo thank you for your note and I appreciate you reaching out to me. I have copied Dr Collins and Dr Tabak to consider the ACTIV forum they have created to bring industry academia and government to consider scientific base approaches That you have described. Dr Collins has organized a vaccine group and I assess could be the best and fastest place to discuss your concept. I am sure they will connect with you soonest

Best

Bob Kadlec.

Sent from my iPhone

On Apr 30, 2020, at 10:02 AM, Gallo, Robert [REDACTED] (b) (6) > wrote:

Dear Dr. Kadlec,

I have not heard from you in over a week. You mentioned getting back to me in a day or two. Time is passing. I am asking you to look at OPV 1 plus 3 serotypes as a bivalent, completely safe vaccine with powerful stimulation of innate immunity lasting several weeks, which can be given a second or third time, and with a historical track record of preventing other infections from entirely different RNA viruses (such as protecting against influenza). Therefore, it should be really helpful for some months, and I think get us past a second wave of SARS-CoV-2, and help people return to work safely. I don't understand delays or apparent lack of interest. Who can possibly be against this? If you hear of hypothetical problems we can show you that these are false. Just ask the questions, and we can give you the evidence.

However, no answer from you suggests no interest and must quickly make alternative pathways. I am though quite surprised and fear you are receiving "fake news" if you will pardon the expression. Some have been against this who defend their old and failed position on polio eradication with their promotion of the use of the inactivated polio virus vaccine. Please note that in the US between 1962 and 1985 we received (safely) the oral polio (OPV). Moreover, if vaccinated already there has not been a single case of a complication and BILLIONS have received it. No it will not last long as innate immunity is short lived, but we strongly believe that we can break the back of the SARS-CoVID-2 spread. Also note that this is what Bill Gates is doing now in India and much of the Eastern hemisphere.

There are countries outside the US wanting to move fast on this. We are waiting for your reply.

Robert Gallo
Director, Institute of Human Virology,
Professor of Medicine and Professor of Microbiology,
UMB, School of Medicine, Baltimore,

And

Co-founder and International Science Advisor of the Global Virus Network (GVN)

From: (b) (6)
Sent: Wed, 29 Apr 2020 13:39:44 -0400
To: Billet, Courtney (NIH/NIAID) [E]
Subject: Fwd: ASF: For review ASAP: draft Sec. Azar Remdesivir statement
Attachments: 4 29 20 remdesivir.docx, ATT00001.htm

Cannot do right now. Go without me

Begin forwarded message:

From: "Billet, Courtney (NIH/NIAID) [E]" (b) (6)
Date: April 29, 2020 at 1:11:19 PM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Cc: "Routh, Jennifer (NIH/NIAID) [E]" <(b) (6)>, "Stover, Kathy (NIH/NIAID) [E]" (b) (6) "Lane, Cliff (NIH/NIAID) [E]" (b) (6)>, "Marston, Hilary (NIH/NIAID) [E]" (b) (6)>, "Conrad, Patricia (NIH/NIAID) [E]" (b) (6)>, "Folkers, Greg (NIH/NIAID) [E]" (b) (6)>
Subject: ASF: For review ASAP: draft Sec. Azar Remdesivir statement

From: Fritz, Craig (NIH/OD) [E] (b) (6)
Sent: Wednesday, April 29, 2020 10:38 AM
To: Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] (b) (6) Routh, Jennifer (NIH/NIAID) [E] (b) (6)>
Cc: Burklow, John (NIH/OD) [E] (b) (6); Myles, Renate (NIH/OD) [E] (b) (6); Fine, Amanda (NIH/OD) [E] (b) (6)>; Wojtowicz, Emma (NIH/OD) [E] (b) (6)>; NIH News Clearance (NIH/OD) <NIHNewsClearance@mail.nih.gov>
Subject: FW: For review ASAP: draft Sec. Azar Remdesivir statement
Importance: High

Hi all – please let us know if you have any comments to the attached.

Thanks!
Craig

From: Brennan, Patrick (OS/ASPA) [REDACTED] (b) (6)>
Sent: Wednesday, April 29, 2020 10:33 AM
To: Fritz, Craig (NIH/OD) [E] [REDACTED] (b) (6)>; Burklow, John (NIH/OD) [E] [REDACTED] (b) (6)>; Myles, Renate (NIH/OD) [E] [REDACTED] (b) (6)>; Fine, Amanda (NIH/OD) [E] [REDACTED] (b) (6)>; Wojtowicz, Emma (NIH/OD) [E] [REDACTED] (b) (6)>; Charrow, Robert (HHS/OGC) [REDACTED] (b) (6)>
Cc: Pence, Laura (HHS/ASL) [REDACTED] (b) (6)>; Hall, Bill (HHS/ASPA) [REDACTED] (b) (6)>; Pratt, Michael (OS/ASPA) [REDACTED] (b) (6)>; Blakeman, Scott (OS/ASPA) <[REDACTED] (b) (6)>
Subject: For review ASAP: draft Sec. Azar Remdesivir statement

NIH and Mr. Charrow,

Below and in the attached is a draft statement from the Secretary regarding the Remdesivir trial – please let me know as soon as you can if this looks OK. (I pulled the frontmatter from the NIH press release.) Thank you!

- Patrick



Patrick Brennan
Director of Speechwriting
Department of Health and Human Services
Office: [REDACTED] (b) (6) | Cell [REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 01:56:42 +0000
To: (b) (6)v
Subject: FW: DRAFT document for WH Briefing Tomorrow
Attachments: Development-Medical-Countermeasures-WH-Briefing 29 April.pptx

Here it is.

From: Collins, Francis (NIH/OD) [E] (b) (6)>
Sent: Tuesday, April 28, 2020 8:08 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: FW: DRAFT document for WH Briefing Tomorrow

Hi Tony,

I called Paul to (b) (5)

(b) (5)
(b) (5)
(b) (5)
(b) (5)
(b) (5)

Francis

From: Mango, Paul (HHS/IOS) <(b) (6)>
Sent: Tuesday, April 28, 2020 7:26 PM
To: Collins, Francis (NIH/OD) [E] (b) (6)>; Kadlec, Robert (OS/ASPR/IO) (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Marks, Peter (FDA/CBER) (b) (6); Woodcock, Janet (FDA/CDER) (b) (6)>; Tromberg, Bruce (NIH/NIBIB) [E] (b) (6)
Subject: DRAFT document for WH Briefing Tomorrow

Thank you all for your timely responses for contributions to this today. Please give this a look and let us know if there is anything glaringly out of place. We will have time to address edits during and after our 930am check in tomorrow. The Secretary may or may not use page 1 during his introductory remarks.

